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PREFACE 
Since the first preliminary report by Opelz et al. (1973a) on the beneficial effect of 
blood transfusions, it has gradually become evident that blood transfusions do have 
such an effect on renal allograft survival. Nevertheless, some physicians are still re-
luctant to adopt a deliberate blood transfusion regimen for fear of sensitization. 
The development of cytotoxic antibodies may delay transplantation for an indefini-
te time for some patients. 
This possible danger of sensitization initially gave rise to the policy of avoiding 
blood transfusions in kidney transplant recipients and it took many years of study, 
experimentation and discussion before the present situation of general acceptance 
was established. 
With respect to the clinical application of a deliberate blood transfusion policy, se-
veral questions remain to be answered regarding the optimal number and the timing 
of transfusions, the antigenic composition of the transfusate and the influence of 
immunosuppressive therapy on the expression of the blood transfusion effect. The 
effect of blood transfusions on kidney graft survival has only been studied in reci-
pients treated with azathioprine and prednisolone for postoperative immunosup-
pression. It still has to be investigated if a beneficial effect of pretransplant transfu-
sions would be demonstrable without conventional immunosuppression or in com-
bination with postoperative administration of the novel immunosuppressant cy-
closporin A. 
Cyclosporin A was recently discovered in the Sandoz Laboratories during a scree-
ning program for antimycotics; its powerful immunosuppressive properties were 
described by Borel et al. (1976). It has been tested in a variety of experimental ani-
mal transplantation models. Preliminary data are available on its clinical effective-
ness and side effects. Some of these side effects are serious and it is still too early to 
be sufficiently informed about the long-term effects of the drug. 
Further questions awaiting evaluation pertain to the optimal dose of the drug, its 
potency to prevent rejection in sensitized recipients, the possible interference with 
other modes of treatment, and the possibilities of conversion to other immunosup-
pressants. 
It was the objective of the present studies to elucidate the items mentioned above. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Kidney transplantation is the present treatment of choice for end-stage renal failure. 
It enables patients to lead a relatively normal life, although the quality of that life is 
threatened by the possible side effects of immunosuppressive therapy. 
Renal transplantation has shown a great increase because a major shift has been ma-
de to cadaveric transplantation. 
By now, over 50,000 kidney transplantations have been performed in man (Rapa-
port, 1981). The supply of cadaver donors has increased due in part to the acceptan-
ce of the criterion of brain death and the improved results of cadaveric transplanta-
tion. In recent years, patient survival following cadaveric kidney transplantation has 
improved, which can be explained by a greater willingness to abandon an allograft 
and to consider a return to dialysis and subsequent retransplantation (Morris, 
1981a; Starzl, 1978). Cadaveric kidney graft survival at one year is more or less pre-
sently fixed at about 50 to 70 percent in the large transplantation centres (13th Re-
port of the Human Transplant Registry, 1977; Starzl, 1978); only some centres show 
a better graft survival (Alexandre, 1978; Me Geown et al., 1980; Lameijer et al., 
1978). 
Rejection is by far the most frequent cause of graft loss today. Despite great advan-
ces in surgical technology and in the development of a reasonably effective immuno-
suppression regimen during the last 20 years, clinical kidney transplantation seems 
to have arrived at a relatively flat plateau of achievement, although there is good 
evidence that this procedure is safer than it formerly was (Rapaport, 1978; Russell, 
1981). Yet, it should be stressed that considerable progress has been made in the 
area of transplantation biology and clinical transplantation (Hamburger, 1979). A 
few examples will be cited. 
It has been recognized that suppressor cells play an important immunoregulatory 
role in transplantation; most of these suppressor cells are T lymphocytes (Brent et 
a!., 1980). Both the T cells and the antibody producing B cells are required for a 
complete immunologic response. Early in the response to a graft, T cell function 
seems to predominate. T lymphocytes have been further divided into subpopulati-
ons such as helper T cells, cytotoxic T cells and suppressor T cells. The latter can be 
defined as cells which suppress the reactivity of other lymphocytes such as cytotoxic 
T cells which contribute to the rejection of a graft. Especially the suppressor cells 
seem to be important in successful take of the graft and they probably play a role in 
the beneficial blood transfusion effect. 
Matching for HLA-DR antigens seems far more important for organ graft progno-
sis in cadaveric kidney grafting than matching for HLA-A and -B antigens (Morris, 
198la). 
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The novel immunosuppressant Cyclosporin A (CyA) is another most promising de-
velopment in present clinical transplantation (Caine, l980b; Starzl, 198\a). 
Monoclonal antibodies may soon find their way to the clinic, although it still has to 
be seen if their application offers better results than those obtained with conventio-
nal antilymphocyte sera (Bainer and Marque!, 1981). 
At present, the three mainstays in clinical kidney transplantation are the admi-
nistration of pretransplant blood transfusions, nonspecific pharmacological immu-
nosuppression and histocompatibility matching. These topics will be considered in 
more detail in this introduction. Ample attention will be given to Cy A as an intro-
duction to the experiments using this novel immunosuppressive agent. 
1.1. BLOOD TRANSFUSION 
Much has been written during the last ten years about the effect of blood admi-
nistration to dialysis patients on subsequent kidney transplant survival. Dialysis pa-
tients were formerly transfused to correct for their anemia. In chronic severe ure-
mia, a normochromic normocytic anemia which persists after institution of dialysis 
is observed. This anemia has been attributed to a shortened red blood cell survival 
time, diminished or no production of erythropoietin and a decrease in response to 
the available erythropoietin. Dialysis can partially compensate for the first and third 
factors by removing toxic substances. Despite intensive medical treatment, blood or 
red cell transfusions are often necessary to bring the very severe anemia to an accep-
table level. In the sixties, this was practiced almost universally. However, multiple 
transfusions and in particular the leukocytes can result in the formation of cytotoxic 
antibodies against donor histocompatibility antigens. 
Sensitization of the recipient is determined by a lymphocytotoxic crossmatch test 
between recipient serum and donor lymphocytes. In the 1960s, it was reported that a 
positive crossmatch test coincided with hyperacute graft rejection (Kissmeyer-
Nielsen eta!., 1966; Patel and Terasaki, 1969). In the former study, the recipients 
were probably hyperimmunized by multiple transfusions. These observations gene-
rally led to great restraint in the administration of blood to prospective kidney graft 
recipients. At about the same time, Dossetor et a!. (1967) found that patients with 
longer surviving grafts had received significantly more blood transfusions. When 
Opelz eta!. (1973a) reported on the beneficial effect of pretransplant blood transfu-
sions on subsequent renal allograft survival, their publication was met with conside-
rable skepticism. Yet, during the following years, many more centres reported a be-
neficial effect of pretransplant transfusions and it gradually became clear that wi-
tholding blood from transplantation candidates resulted in an extremely low kidney 
graft survival. Several articles in recent years have reviewed the retrospective data 
that in the majority supported the transfusion effect (Opelz and Terasaki, 1977; van 
Es and Balner, 1979; Solheim, 1979; Opelz eta!., 1979a). 
In the meantime, much experimental work had been done in animal models, which 
unequivocally gave evidence of the existence of a uansfusion effect (van Es et a!., 
1977; Obertop eta!., 1978b; Fabre et al., 1978; Marque! and van Bekkum, 1973). 
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During the last three years, several prospective studies from single centres (Persijn et 
al., 1979; Williams et al., 1979) or multicentre analyses (Spees et al., 1980; Opelz 
and Terasaki, 1980a) have confirmed the earlier retrospective data. 
The existence of a beneficial blood transfusion effect is now generally accepted, 
although some controversies still remain (Opelz et al., 1981a). These controversies 
pertain mainly to the policy that should be followed to obtain an optimal transfusi-
on effect. In the first place, it is desirable to know the minimal number of transfusi-
ons that is effective in prolonging kidney graft survival; secondly and related to the 
first item, it is essential to have information on the sensitizing effect of a given num-
ber of transfusions. Sensitization not only renders potential recipients untransplan-
table, but transplant outcome is also worsened in highly sensitized patients. Opelz et 
al. (1981c) have shown in a large retrospective and prospective multicentre study 
that the frequency of sensitization has been overestimated on the basis of previous 
retrospective studies (Russell, 1977; Solheim, 1979; Glass, 1980). In the study of 
Opelz et al. (1981c), it was prospectively shown that highly reactive antibodies (anti-
bodies exhibiting) 90"7o reactivity against a random test panel) did not occur in any 
of the male recipients or in females that had not previously been pregnant after up 
to 20 transfusions. Almost 90% of the male patients were practically unresponsive 
( (10% antibody reactivity against the panel). The situation was quite different for 
women with previous pregnancies; 10% of these developed highly reactive antibo-
dies after 10 transfusions. Also T cell antibodies were more frequent in females. In 
the retrospective part of the study, the frequencies for all of these categories were 
higher. As opposed to what had previously been assumed, only one-third of the pa-
tients who became sensitized and received additional transfusions showed an increa-
se in antibody reactivity, while one-third showed a decrease. The recipients showing 
an increase in antibody reactivity were also predominantly females who had had 
previous pregnancies. Further, recent evidence has been presented by the Los Ange-
les group that recipients showing a decrease in antibody levels after additional trans-
fusions fare very well after transplantation (Opelz et al., 1981a). In several re-
trospective as well as prospective studies, the same group showed that an increasing 
number of transfusions is correlated with better graft survival (Opelz and Terasaki, 
1980a, 1980b). Only 3% of the patients became highly sensitized (Opelz et al., 
1981b) with consequent poor graft prognosis. 
The desirable number of transfusions is one of the controversies alluded to. Some 
authors reported that after only one transfusion an extremely high one-year graft 
survival of approximately 80 percent was obtained (Persijn et al., 1977; Williams et 
al., 1979). Others found an optimal effect of about 5 transfusions, more transfusi-
ons exhibiting no additional benefit. The dose (i.e., number) effect as reported by 
Opelz and Terasaki was also confirmed by both Spees et al. (1980) in a large 
prospective study initiated by the Southeastern Organ Procurement Foundation and 
Fehrman et al. (1980). 
Variable results have also been published regarding the blood products used. In the 
multicentre data analysed by Opelz and Terasaki, it was consistently found that fro-
zen blood was less effective than whole blood, packed cells or washed packed cells 
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(Opelz and Terasaki, 1980a, 1980b). Two groups reported on a beneficial effect of 
frozen blood (Polesky et al., 1977; Fuller et al., 1977, 1982). Huggins et al. (1973) 
claim that frozen deglycerolized red blood cells cause less sensitization and are less 
frequently followed by serum hepatitis as compared with whole blood. They distin-
guish between erythrocytes deglycerolized by centrifugal washing and by agglomera-
tion. The centrifugation method would leave more leukocytes viable and this would 
explain a higher sensitization rate, which was however not significant. Blood degly-
cerolized by centrifugation led to significantly better graft survival (Fuller et al., 
1982). The importance of leukocytes for the induction of the transfusion effect was 
also demonstrated by the Leiden group (Persijn et al., 1979), which reported that 
leukocyte-free (cotton-wool-filtered) blood had virtually no beneficial effect on 
graft survival; washed erythrocytes showed about the same results as one blood 
transfusion of unidentified composition. lt seems that leukocytes may be necessary 
for inducing a transfusion effect, but it should be realized that their administration 
also carries a considerable risk of recipient sensitization. It has been demonstrated 
that deliberate buffy-coat transfusions lead to excessive antibody formation (Taka-
hashi H. et al., !982). Nothing is known at present about the effect of plasma or pla-
telet transfusions on graft survival. Recent evidence obtained in the rhesus monkey 
suggests that platelet-rich plasma is less immunogenic than fresh blood. In addition, 
blood stored for 3 weeks or more proved to be significantly less immunogenic than 
blood stored for 2 weeks or less (Oh et al., 1982). The latter finding was also confir-
med in man following donor-specific transfusions using stored blood older than 4 
days (Light et al., 1982). 
Although it has been claimed by some authors that the time interval between the 
last transfusion and transplantation influences the outcome of transplantation, this 
was not demonstrated in other series (Persijn et al., 1979; Opelz et al., 1979a; Corry 
et al., 1980) and also the prospective data of the International Workshop Study 
(Opelz and Terasaki, 1980b) provided evidence that the transfusion-transplantation 
interval is irrelevant. The possible effect of such an interval could be ascribed to the 
fact that patients receiving a transfusion shortly before transplantation generally 
had previously received multiple transfusions. 
Another controversial topic concerns the effectiveness of blood transfusions gi-
ven during operation. Although some centres report a beneficial effect of peropera-
tive transfusions (Stiller et al., 1978; Hunsicker et al., 1980; Williams et al., 1980), 
others contradict them. The International Workshop Study could not support a be-
neficial effect on graft survival. 
Likewise, the latter study could not confirm that the time length of dialysis was cor-
related with graft survival, as was found by others (Guttmann, 1978; Fehrman et 
al., 1979). Dialysis time appeared to be irrelevant and graft survival proved to be 
primarily related tot the number of transfusions given before transplantation. 
Festenstein et al. (1976) found blood transfusion to be maximally effective in 
well-matched (i.e., for 3 or 4 HLA-A or-B antigens) recipients. Opelz and Terasaki 
(1980a) reported a beneficial effect of transfusions independent of the number of 
antigens matched. The results of the International Workshop Study showed the 
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most prominent beneficial effect of histocompatibility matching in nontransfused 
recipients. This effect of HLA matching on graft survival decreased with an increa-
sing number of transfusions, i.e., with a greater improvement of graft survival me-
diated by transfusions. This outcome was similar for both HLA-A, -Band -DR mat-
ching. Nevertheless, transfused patients with better matches showed a superior graft 
survival, although not significant. Apparently the administration of blood transfu-
sions and matching are not really additive; transfusions probably improve graft sur-
vival to a level where additional HLA matching has little influence. 
Matching not only of the kidney donor but also of the blood donor may influence 
graft survival. Persijn et al. (1979) observed that the HLA type of the blood transfu-
sion donor had no bearing on graft survival in their study using a one transfusion 
protocol. Recently, interest has focused on the application of well-matched blood 
transfusions, in the hope that this might prevent sensitization while retaining the be-
neficial transfusion effect. Nube et al. (1981) reported a favourable effect of two or 
three HLA-A and -B matched leukocyte-poor transfusions which was comparable 
with the effect of one random leukocyte-poor transfusion in the same centre. Sensi-
tization seemed to be less than for one random transfusion. 
On the other hand, Albert et al. (1981) administered one or three HLA-A, -B mat-
ched transfusions with an average mismatch of 0.86 and found no significant de-
crease in antibody production and no definite beneficial effect of transfusion. 
Another new development in "transfusion therapy" is the administration ·or 
donor-specific tranfusions to one-haplotype related recipients (Salvatierra et al., 
1980). It has been demonstrated that third-party blood transfusions also have a be-
neficial effect on graft survival in one-haplotype related transplantations (Opelz et 
al., 198la). The protocol of donor-specific transfusions was started to prospectively 
select incompatible one-haplotype related donor recipient pairs and to alter the reci-
pient immune response. It appeared that 300Jo of the potential recipients became 
sensitized against their blood donor but not against a random panel. Consequently, 
these sensitized patients did not recieve the respective related transplant, but were 
still suitable candidates for cadaver transplantation. A very favourable effect of the-
se donor-specific transfusions was observed in nonsensitized patients transplanted 
with one-haplotype identical related kidneys, with one- and two-year survival rates 
of 980Jo and 95%, respectively (Salvatierra et al., 1981; Mendez et al., 1982). Ape-
culiar finding when using this donor-specific transfusion protocol was that in many 
cases early, relatively mild, rejection crises which were quite amenable to therapy 
and seldom resulted in graft loss were seen (Salvatierra et al., 1982; Takahashi I. et 
al., 1982; Leivestad et al., 1982). In sharp contrast donor-specific transfusions from 
nonrelated individuals were followed by an extremely low graft survival (Ruzany et 
al., personal communication). Probably the implantation of a graft, following ad-
ministration of blood containing the same histocompatibility antigens creates a 
donor-specific sensitization, which is not compensated for by the benefits of there-
lated situation. 
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1.1.1. MECHANISM 
Several hypotheses have been proposed to explain the working mechanism that un-
derlies the beneficial effect of pretransplant blood transfusions. 
In their initial publication, Opelz et al., (1973a) offered two possible explanations. 
In the first place, blood transfusions may act by a selection of the potential reci-
pients into responders and nonresponders. Patients who have received many ran-
dom blood transfusions and do not respond with lymphocytotoxic antibody forma-
tion are nonresponsive. This state of nonresponsiveness will also be reflected in a 
better acceptance of a subsequent kidney graft. On the other hand, responders easily 
produce antibodies after a few transfusions. These antibodies not only make it more 
difficult to find a suitable kidney donor but they are also a reflection of a more vigo-
rous immune response towards a prospective graft which may eventually result in re-
jection. As a second hypothesis, it was suggested that blood transfusions induce a 
state of recipient unresponsiveness, probably by means of the formation of enhan-
cing antibodies. The selection principle has been quoted for several years as the me-
chanism of action of blood transfusions. However, the demonstration of a transfu-
sion effect in HLA-identical sibling transplantation makes this theory unlikely, at 
least as the sole mechanism (Opelz eta!., 198la). It cannot be excluded that selection 
plays a role in cadaver transplants. It definitely plays a role in some protocols apply-
ing donor specific blood transfusions in one-haplotype related kidney transplantati-
on (Salvatierra et al., 1981). 
The second hypothesis that blood transfusions would induce decreased immune 
reactivity was suggested by the finding that the plasma of dial) ;is patients and pa-
rous women contained a factor that blocked the mixed leukocyte reaction (Sengar et 
a!., 1973). It was speculated that nonreactivity as a result of blood transfusions 
might be due to enhancing antibodies. Such antibodies have been demonstrated in 
skin transplantation in mice and kidney transplantation in rats and have been shown 
to exhibit a protective effect on graft survival (Jeekel and Westbroek, 1971; Stuart 
eta!., 1968). Yet, enhancement is unlikely to play a role, since the transfusion effect 
in cadaver kidney recipients is not donor specific and because a single random trans-
fusion is already effective. For the latter reasons, "classical" tolerance can also be 
ruled out as a likely causative phenomenon (van Rood and Balner, 1978). Also pre-
formed cold B-cell antibodies have been implicated as being responsible for impro-
ved graft survival (Iwaki eta!., 1979). However, an association between the admi-
nistration of blood transfusions and the occurrence of pretransplant autoreactive 
B-cell antibodies could not be proved and this makes their role in the transfusion ef-
fect unlikely (Opelz eta!., 198lc). Further, anti-idiotypic antibodies have been assig-
ned a role in the transfusion mechanism (Biihlmann et al., 1978). In a recent study, 
it was found that anti-idiotypic antibodies could be shown only in recipients who 
had recieved pretransplant blood transfusions. In transfused recipients, these anti-
bodies were demonstrable only in patients with functioning grafts and not in pa-
tients who had rejected the graft (Singal eta!., 1982). These IgG antibodies caused 
inhibition in the MLR and were directed against responder T cells. The authors sug-
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gest that anti-idiotypic antibodies could be induced by blood transfusions and these 
antibodies might be responsible for enhanced renal allograft survival. Other eviden-
ce for the existence of humoral factors that may play a role in evoking the beneficial 
transfusion effect has been presented by Proud et al. (1979), who showed that the 
plasma of multitransfused patients contained inhibiting activity that was related to 
the alpha-2-macroglobulin fraction. Keown and Descamps (1979) have proposed the 
hypothesis that blood transfusions would have a nonspecific immunosuppressive ef-
fect on the host immune system via a temporary functional modulation in mononu-
clear phagocytes. The transiently impaired function of mononuclear phagocytic cell 
function occurred after ingestion of altered red blood cells in vitro. Although it is an 
interesting hypothesis, the reported ineffectiveness of leukocyte-free blood transfu-
sions (Persijn et al., 1979) makes it very improbable that the mechanism mentioned 
is the only factor responsible for the beneficial transfusion effect. 
The argument has been advanced that the observed effect of pretransplant blood 
transfusions was merely a reflection of the duration of dialysis-dependent uremia, 
because a correlation was found between the number of transfusions and the time 
length of dialysis. However, experiments in animals suggest an immunosuppressive 
effect of pretransplant blood transfusions, as no uremia effect was observed in these 
healthy animals (Marquet et al., 1971; vanEs et al., 1979; Obertop et al., 1978b). 
Much recent work provides indirect evidence for a role of suppressor T cells in the 
blood transfusion effect. Fischer et al. (1980) found a marked suppression of cellu-
lar immunity after transfusion of third-party washed blood cells. A subsequent 
transfusion induced a more pronounced immunosuppressive effect. This phenome-
non of immune suppression was not seen after transfusion of autologous blood in 
human volunteers. In a more recent communication, the same group reported that 
third-party cells were also inhibited in the suppressor MLR after transfusion. Fur-
ther, Con A inducible suppressor activity was low during the first two weeks follo-
wing transfusion and increased thereafter; the initially low suppressor activity coin-
cided with a transient decrease in suppressor cells posttransfusion (Lenhard et al., 
1982). The authors concluded that blood transfusions initially induce a nonspecific 
suppression of cellular immunity, probably mediated by monocytic cells, whereas 
increasing suppressor T-cell activity is present in a later phase; it was suggested that 
at least two cellular graft protective mechanisms are induced by blood transfusions. 
A suppressive effect of transfusion on cellular immunity, although limited to PHA-
induced mitogenesis, was also found by Borleffs and Marquet (1981) in rhesus mon-
keys. Smith et al. (1981) showed a decrease in suppressor T -cell activity one week af-
ter transfusion of packed red cells in hemodialysis patients; this was followed by an 
increase in suppressor cell function twee weeks later. This increased suppressor 
T-cell function disappeared after five months. These data are in accord with the 
above-mentioned findings of Lenhard et al. 
The finding that the blood transfusion effect is independent of the transfusion-
transplantation interval (Opelz and Terasaki, 1980b) is not in agreement with the 
presumed suppressor T-cell activity as the only mechanism for explaining the benefi-
cial transfusion effect if the above findings of Smith et al. are taken into account. 
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Finally, Marque! et al. (1982) demonstrated that suppressor cells can be the causati-
ve factor in prolonged graft survival following donor blood transfusion in a hetero-
topic heart allograft model using the BN/Ro and W AG/Ro rat strains as donors 
and recipients, respectively. 
Reviewing all the data presented above, it is likely that more than a single immuno-
logic phenomenon can be held responsible for the transfusion effect. Suppressor T 
cells rank high on the list of proposed factors. 
1.1.2. SENSITIZATION 
In the preceding pages, attention has been focused several times on the sensitizing 
effect of blood transfusions. However, antibodies against leukocytes may also deve-
lop as a result of pregnancy or graft rejection. About 30-60"7o of all patients waiting 
for a kidney transplant will have these antibodies (Ting, 1981). Antibodies are detec-
ted by screening the sera from dialysis patients against the lymphocytes of a random 
panel of volunteers. The presence of lymphocytotoxic antibodies to kidney donor 
cells, i.e., a positive crossmatch, was until recently a contra-indication for trans-
plantation, since it had been demonstrated that a positive serological crossmatch 
could result in accelerated graft rejection (Kissmeyer- Nielsen et al., 1966; Patel and 
Terasaki 1969). At that time, it was still believed that these lymphocytotoxic antibo-
dies were directed at HLA-A and -B antigens. Now it is known that antibodies are 
also directed at other antigen systems on the lymphocyte cell surface. 
Antibodies to some of these antigens are not associated with graft loss and conse-
quently a transplantation with a positive crossmatch can sometimes be carried out. 
By various screening procedures it is often possible to determine the specificity of 
these antibodies. 
Lymphocytotoxic antibodies can be reactive with Tor B cells. Reactivity with T and 
B cells may indicate the presence of HLA-A, -B or -C or autoreactive antibodies. 
Reactivity with B cells only may indicate the presence of HLA-DR, autoreactive, 
Lewis or weak HLA-A, -B, -C antibodies. Reactivity with T cells only may be due to 
T-cell alloantigens (Ting, 1981). It has been reported that kidneys may be transplan-
ted in the presence of a positive B-cell crossmatch with a low risk of failure (Ting 
and Morris, 1977; Morris et al., 1977), although a hyperacute rejection has been re-
ported (Dejelo and Williams, 1977). Certain B-cell antibodies appear to be associa-
ted with graft rejection and others with improved survival. B-cell antibodies can be 
detected at a temperature of either 5'C or 37'C. The cold B-cell antibodies (detected 
at 5'C) are autoreactive lgM immunoglobulins (lwaki et al., 1979; Jeanne! et al., 
1980). The pretransplant cold B-cell antibodies are not induced by blood transfusi-
ons but rather by viral infections (Opelz et al., l981c). Warm B-cell antibodies are 
considered to be directed against HLA-DR antigens and are lgG in nature. Anti-
HLA-DR antibodies seem to be the equivalent of anti-Ia antibodies in rodents. Al-
though Jeekel et al. (1976) could not demonstrate an enhancing effect of anti-LD 
antibodies in their rat kidney graft model, anti-la antibodies can have an enhancing 
effect on graft survival in rodents. Anti-HLA-DR antibodies in humans have rather 
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been shown to exert a deleterious effect in kidney transplantation (Sirchia et a!., 
1979, Ayoub et a!., 1980). Both autoreactive and anti-HLA-DR antibodies have 
been reported to result in a minority of positive B-cell crossmatches (Ettenger et a!., 
1979; d' Apice and Tait, 1980). 
Hyperacute rejection has been frequently observed with positive T-cell crossmatches 
(Opelz eta!., 1979b), but it is relatively safe to perform a transplant with a positive 
B-ee!! crossmatch (Ettenger et al., 1976; Ting and Morris 1977; Reekers, 1982). Ho-
wever, it does not seem safe to transplant with a positive B-ee!! crossmatch (Ting 
and Morris, 1981) when non-autoreactive B-cell antibodies are present, when B-cell 
antibodies have developed after a failed graft and when anti-HLA-A, -B or -C anti-
bodies are present. 
1.2. IMMUNOSUPPRESSION 
After initial attemps in France (Dubost et al., 1951; Kiiss et al., 1951) and in the 
USA (Hnme et al., 1952) to transplant human kidney allografts without postopera-
tive immunosuppression, it became clear by the middle of the 1950s that ways had to 
be found to suppress the immune response. As it was already known at that time 
that identical twins did not reject each other's tissues, the problem of rejection was 
circumvented in the first transplantation between monozygotic twins by Murray and 
associates in 1954. Meanwhile, it had been shown that total body irradiation could 
induce prolonged survival of kidney allografts in dogs. At the end of the 1950s, total 
body irradiation was introduced in clinical renal transplantation, but the results we-
re not favourable. 
1.2.1. AZATHIOPRINE AND PREDNISOLONE 
Schwarz and Dameshek (1959) showed that the antimetabolite 6-mercaptopurine 
could induce a persisting immunosuppressive state in rabbits. Using this compound, 
prolonged renal allograft survival could be obtained in dogs (Caine, 1960). Azathio-
prine, an analogue of 6-mercaptopurine, was subsequently found to have a better 
immunosuppressive effect in the dog renal allograft model and to predispose to fe-
wer infections (Caine, 1961). The clinical application of azathioprine as an immuno-
suppressive agent in human kidney transplantation soon followed. The experimen-
tal basis for the use of corticosteroids was laid by Billingham et al. (1951) and their 
usefulness in immunosuppressive therapy was soon confirmed by many others. Sin-
se the beginning of the 1960s, the combination of azathioprine and corticosteroids 
has been the "sheet anchor" of clinical immunosuppression. Although reasonably 
effective, the immunosuppressive potency of this regimen is far from optimal, as re-
flected in the average one-year survival rate of cadaver kidney transplants, which 
amounts to only slightly more than 50"7o. 
The associated side-effects of azathioprine and corticosteroids also represent a ma-
jor problem. Many of these side-effects such as the Cushingoid appearance, avascu-
lar necrosis of bone, diabetes and cataracts can be attributed to the steroids. Cardio-
21 
vascular and cerebrovascular disease have currently replaced infection as a major 
cause of death after transplantation (Morris, 198la); however, infections remain a 
problem. Increased incidences of malignant lymphomas and other tumors have also 
been reported (Penn, 1979, 1981). Further reported complications of chronic con-
ventional immunosuppression are gastrointestinal ulcerations, pancreatitis, hyper-
parathyroidism, hypersplenism, liver malfunction and hyperlipidemia (Starzl et a!., 
1977). To diminish the side-effects related to steroid administration, several schedu-
les for decreasing the total dose administered and consequently the inherent side-
effects have been developed. Both alternate-day corticosteroid therapy (Fauci, 1978) 
and low dose steroid therapy (McGeown eta!., 1980; Chan eta!., 1980) have been 
shown to be as effective as high continuous doses in preventing graft rejection. Also 
recommendations have been made for a maximum total dose of 2 g of steroids in in-
travenous "pulse therapy" to reverse rejection crises (Kumar et a!., 1978). Side-
effects specific for azathioprine seem to be mainly related to its hepatotoxic effect 
(Schein and Winokur, 1975) and to the leucopenia resulting from its bone marrow 
toxicity. 
Although side-effects which are mainly related to the corticosteroids used may be se-
vere, conventional immunosuppression consisting of azathioprine and prednisolone 
(Aza/Pred) is still indispensible, because it is the best documented and therefore at 
present safest immunosuppressive therapy. While awaiting the final evaluation of 
the new promising agent Cyclosporin A (CyA), the low dose steroid therapy as pro-
pagated by McGeown et al. (1980) provides satisfactory immunosuppression with 
an acceptable number of unwanted side-effects. 
1.2.2. CYCLOSPOR!N A 
Cyclosporin A (CyA) is a fungal metabolite which exhibits a very strong immuno-
suppressive effect in addition to weak antifungal activity. It was isolated at the San-
doz Laboratories from the soil fungi Trichoderma Polysporum Rifai and Cylindro-
carpon Lucidum in a screening program for antibiotic agents. CyA is a nonpolar cy-
clic peptide consisting of 11 amino acids. One of these amino acids is unique and 
most are hydrophrobic, which explains its insolubility in water. The compound has 
a molecular weight of 1202.6 daltons and the molecular formula is c62H 111 N 11012. 
The antibiotic spectrum is very narrow; only few yeast species are sensitive to CyA 
and bacterial growth is not inhibited. Its immunosuppressive activity was first 
shown by Borel and co-workers (1976, 1977). The Cambridge group was the first to 
report marked prolongations of survival of vascularized organ allografts in animals 
(Kostakis et a!., 1977; Calne and White, 1977); toxic effects were then still seen be-
cause of the lack of experience with the drug. Since 1977, many reports have appea-
red on the effect of Cy A in various transplantation models using several species. A 
review of the various animal transplantation experiments is given in Tabel1.2.2.A. 
Clinical transplantation studies have also been initiated in a number of centres 
which are concerned with kidney, pancreas, liver and heart transplants (Calne et a!., 
1981a; Starzl eta!., 198lb; Oyer eta!., personal communication). 
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In the following, some studies will be discussed in more detail. 
Experimental transplantation 
Rat. Most experiments using CyA have been performed in rats. Kidney and heart 
graft rejection can be suppressed by a short course (1 week) of CyA administered 
orally or intramuscularly (Homan et al., 1980e; Kawahara et al., 1980; Niessen et 
al., 1982a). This effect is dose-dependent and at an adequate dose indefinite graft 
survival is even achieved. If treatment with CyA is delayed until4 days after trans-
plantation, renal allograft rejection is no longer suppressed (Homan et al., 1980e), 
suggesting that the drug is effective mainly when administered at an early stage of 
the immune response. CyA is also far less effective in suppressing renal allograft re-
jection in recipients sensitized by a previous donor skin graft (Homan et al., 1980f). 
Table 1.2.2.A. Transplantation experiments in various species using cyclosporin A for postoperative 
immunosuppression. 
Species 
mouse 
rat 
rabbit 
dog 
monkey 
pig 
transplant 
skin 
bone marrow 
kidney 
heart 
pancreas 
skin 
bone marrow 
nerve 
kidney 
skin 
cornea 
kidney 
lung 
pancreas 
skin 
bone marrow 
kidney 
heart 
heart 
reference 
Lems et a!., 1980 
Borel and Meszaros, 1980 
van Bekkum eta!., 1980 
Borel eta!., 1976 
Homan et al., 1980 
Simms et a\., 1980 
Kostakis et al., 1977 
Kawahara et al., 1980 
Niessen et a!., 1982a 
Rynasiewicz et al., 1980 
Garvey et a!., 1980 
White et al., 1980 
Tutschka et al., 1979 
Borel et a!., 1976 
Zalewski and Gulati, 1981 
Dunn et a!., 1978 
Green and Allison, 1978 
Gratwohl eta!., I98lb 
Shepherd et a!., 1980 
Caine and White, 1977 
Homan et a!., 1980a 
Niessen et al., 1981 
Veith eta!., 1981 
McMaster eta!., 1980 
Deeg et al., 1980 
Deeg et al., 1981 
Borleffs eta!., 1981 
Jamieson eta!., 1979 
Calne et al., 1978 
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These data indicate that Cy A might be less effective in sensitized recipients and are 
also supported by in vitro findings demonstrating that the secondary MLR response 
is only poorly inhibited by CyA, while it has no effect on the generation of cytotoxic 
effector cells. In contrast to the above data, it was found in our WAG/Ro to 
BN/Ro heart allograft model in the rat that sensitization by donor blood could be 
overcome and that even permanent graft survival can be achieved at a dose of 15 
mg/kg/day CyA given intramuscularly for 7 days (Niessen eta!., 1982a). Prelimina-
ry results in the same model indicate that the source of the sensitizing donor antigen 
is important for the resulting strength of the rejection response, which must be over-
come. For example, high dosis of CyA (up to 30 mg/kg/day) are necessary to obtain 
permanent heart graft survival in some recipients sensitized by a donor heart in the 
WAG/Ro to BN/Ro combination, whereas only moderately prolonged graft survi-
val can be obtained following sensitization by donor skin at the same doses of Cy A 
(unpublished observations). Although a short course of CyA can induce permanent 
heart or kidney allograft survival, this could not be achieved in vascularized segmen-
tal pancreatic allografts; grafts were rejected after discontinuation of therapy (Ry-
nasiewicz eta!., 1980). Prolongation of islet allograft survival could only be obtai-
ned across a minor histocompatibility barrier. Skin allografts were likewise rejected 
after termination of therapy (White eta!., 1980); this was also observed in the mou-
se (Lems eta!., 1980). The survival of cardiac xenografts from the Syrian hamster to 
the Lewis rat was found to be prolonged by high doses of CyA (35 mg/kg/day for 2 
weeks) but only to a very limited extent (3 weeks) (Homan eta!., 198la). A similar 
experiment of Marque! et a!. using the hamster to W AG/Ro rat model showed a 
prolongation of only a few days at equally high doses of CyA; this discrepancy can 
probably be explained by the stronger immunogenecity of the latter model. 
In the rat, the suppression of the immune response by CyA seems to be both specific 
and nonspecific. During the administration of the drug, immune reactivity is 
nonspecifically suppressed. When the administration is discontinued, this stage is 
followed by an "unstable" period during which a secondary challenge with donor 
skin results in rejection of this skin graft as well as of the initial heterotopic heart 
graft; a third party secondary skin graft can in some cases also cause rejection of the 
initial heart graft in this period (Nagao eta!., 1982). There is eventually a third pha-
se during which only donor-specific skin grafts are tolerated. It was found that the 
lymphocytotoxic response to third-party allografts was suppressed in rats with these 
long-term surviving kidney allografts (Homan et al., 1979). This tolerant state pro-
ved to be similar to that found in enhanced organ graft recipients, irrespective of the 
way this state was induced (Morris, 198Ib). Hutchinson eta!. (198la) found eviden-
ce for the existence of specific suppressor cells from 12 days after transplantation 
and following administration of CyA for 7 days after grafting. 
Rabbit. Also in rabbits a short course of CyA proved to be sufficient for indefinite 
kidney allograft survival. The tolerance induced was found by some authors to be 
specific (Green eta!., 1979) but nonspecific by another (Dunn, 1981). Although it 
was not investigated, the same pattern as in the rat might be found. Also compara-
ble to the rat is the rejection of skin grafts after stoppage of CyA administration. 
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Cy A does not prevent rejection of second-set skin grafts in recipients previously sen-
sitized with donor skin (Gratwohl et al., 1981). 
Dog. In the dog, a clear dose-response relationship in the prevention of renal allo-
graft rejection was observed (Homan et al., 1980a; Niessen et al., 1981). CyA at a 
dose of 20-25 mg/kg/day is sufficient to maintain graft survival in all cases. In reci-
pients treated with CyA as the only immunosuppressant, rejection is always seen af-
ter discontinuation of the drug. If recipients were transfused before operation and 
treated with the combination of CyA and Aza/Pred, prolonged kidney graft survi-
val was obtained in 500Jo of the recipients when CyA was stopped and Aza/Pred 
continued (Niessen et al., 1982b); this prolonged survival could be attributed to the 
expression of the blood transfusion effect, which proved to be manifest only on 
treatment with Aza/Pred and not when CyA was used for immunosuppression 
(Niessen et al., 1981). In contrast to the findings in the rat, prolongation of kidney 
graft survival could nevertheless be achieved in some animals when CyA was admi-
nistered starting on day 4 after transplantation; still, this indicates that also in out-
bred animals the value of the drug for the reversal of rejection crises is limited (Ho-
man et al., 1980d). Beginning rejection of skin allografts could be prevented but re-
jection eventually occured after termination of CyA treatment (Deeg et al., 1980). 
Survival of vascularized segmental pancreatic allografts could be maintained only at 
high doses of CyA (up to 40 mg/kg/day) (Du Toit et al., 1982), whereas whole-
organ pancreas allografts were rejected at a median survival time of 85 days at doses 
of 18 to 25 mg/kg/ day (McMaster et al., 1980). 
CyA was found to be relatively nontoxic in the dog. No signs of nephrotoxicity have 
been observed (Homan et al., 198Ic; Niessen et al., 1981), not even in dogs receiving 
a kidney with poor function because of ischemic damage (Homan et al., 1980c). Li-
ver function abnormalities resulting in jaundice have been reported, but high dosa-
ges of the drug (50 mg/kg/day) were used in that series (Caine et al., 1979b). In the 
same study, a considerable number of pulmonary infections was noted, although 
white cell counts did not fall significantly. Others found no significant increase in 
infectious complications. A side-effect which seems to be related to the use of high 
doses is the tendency to lose weight (Caine et al., 1979b; Du Toit et al., 1982). Gum 
hypertrophy, which also occurs in humans, was observed in dogs given high doses of 
CyA. 
Monkey. Kidney graft rejection could be effectively suppressed by CyA in the rhe-
sus monkey (Cosimi et al., 1978); doses of 10 mg/kg/day and 25 mg/kg/day were 
found to be about equally effective (Borleffs et al., 1981). In cynomolgus monkeys, 
heterotopic heart allograft survival was shown to be significantly prolonged using 
Cy A; in combination with anti thymocyte globulin (ATG), a high incidence of infec-
tion as well as lymphoma formation was seen (Pennock et al., 1981). In the latter 
study, the combination therapy was not more effective than CyA alone in terms of 
graft survival. Except for the reports of the Stanford group (Pennock et al.), no 
lymphoma formation has been noted by other investigators using CyA at therapeu-
tic doses for a long period of time in the monkey. The same applies to the high fre-
quency of infections (Borleffs et al., personal communication). Aside from the pro-
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found immunosuppression caused by the combination of CyA and ATG (as reflec-
ted in the high number of infectious complications), contamination with a lympho-
ma inducing virus is probably also reponsible for the development of these tumors 
(Bieber, personal communication). 
Clinical transplantation 
Cy A has been proved to be an extremely potent immunosuppressant also in man. By 
now, over 300 kidneys have been transplanted using CyA for immunosuppression, 
either alone or in combination with conventional immunosuppressants, in particular 
steroids. At the beginning, when CyA was used with other immunosuppressants, se-
veral patients developed severe infections (Calne et al., 1979a; Sweny et al., 1981). 
Calne et al. felt that the immunosuppression brought about by combination therapy 
was excessive and they consequently advised that CyA be used preferably as a single 
agent and to confine the use of corticosteroids to the intravenous treatment of rejec-
tion crises (Calne et al., 1981a). On the other hand, it has been proposed by Starzl et 
al. (1980) that not the nephrotoxic effect of Cy A but early rejection may be the cau-
se of renal malfunctioning; they recommended the combined use of CyA and pred-
nisone to anticipate rejection. They noted that rejection in their liver patients was 
usually easy to control with small increases in prednisone when used concomitantly 
with CyA. Morris et al. (1981b) frequently found signs of cellular rejection in routi-
ne posttransplant biopsies while using Cy A. Therefore, they favour the addition of 
steroids to prevent renal damage from chronic rejection. 
The main problem in the use of CyA is its nephrotoxicity. This has been unequivo-
cally established since the first reports of Calne et al. (1978b); it was observed not 
only in kidney transplant patients but also in bone marrow (Powles et al., 1980) and 
liver transplant recipients (Klintmalm et al., 1981). This awkward side effect, which 
also complicates the ready recognition of rejection, is fortunately reversible and can 
usually be managed with a reduction in the CyA dosage. However, kidney function 
is poorer in CyA patients than in Aza/Pred patients (Hamilton et al., 1981) and se-
rum creatinine levels usually decrease after conversion from CyA to Aza/Pred (Cai-
ne et al., 1981b; Morris, 198lb). Another dose-dependent side effect of CyA is the 
hepatotoxicity which has been noted by several investigators (Starzl et al., 1981a; 
Calne et al., 1981a). This occurred less frequently than nephrotoxicity and could 
also be managed by reduction in dosage. Following the study of Calne et al. (1979a) 
reporting the occurrence of lymphomas in patients treated with CyA, the oncogene-
city of the drug has remained a subject of continuous concern. The occurrence of 
lymphomas is probably related to excessive immunosuppression. Up to now, 5 of 
300 renal allograft patients treated with CyA have developed a lymphoma and, ex-
cept for one, they all had received additional immunosuppressants. This is one rea-
son why Calne advises that CyA be preferably used not in combination with other 
immunosuppressants. Starzl, who uses prednisone concomitantly, had one patient 
of 123 transplant recipients with a lymphoma. Although one should remain alert 
considering the present data on Cy A, there is no reason to preclude its further use in 
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humans. Other side effects in man are hirsutism, benign mammary fibroadenomas 
(RoUes and Caine, 1980), gum hypertrophy, tremor, neuresthesia and depressive 
psychoses (Caine et al., l979a; Powles et al., 1980). Monitoring of CyA serum levels 
for clinical use has now become possible with a radioimmunoassay (Keown et al., 
1981) or high pressure liquid chromatography (Gratwohl eta!., 1981b). There is a 
good correlation between the serum level and the immunosuppressive activity, but 
the correlation between serum creatinine and Cy A levels seems to be poor and it is 
not quite clear which level of the drug is nephrotoxic. CyA is variably absorbed and 
reaches a peak serum level 3-4 hours after administration; it is taken up by the liver 
and excreted via the bile (Taylor, 1980). 
Of course, this potent drug has not been used only in kidney transplantation. In li-
ver transplantation, lower doses of CyA (10 mg/kg/day) seem to be sufficient to 
suppress graft rejection. Hepatotoxicity appeared to be a minor problem (Caine et 
al., 1981a; Starzl et al., 1981 b). Also in liver transplantation, Starzl added predniso-
ne to cope with chronic rejection. Pancreas transplantation could be another indica-
tion to use CyA. Several pancreases have been transplanted, some in combination 
with kidney or liver transplants (Caine et al., 1981a). The results so far have been ra-
ther disappointing; graft failure was attributable to both chronic rejection and fi-
brosis of the exocrine pancreas caused by the occlusion of the pancreatic duct with 
Latex. This program has been abandoned for the time being. In bone marrow trans-
plantation, Cy A is very effective in preventing acute Graft Versus Host Disease 
(GVHD) (Powles et al., 1980) if administration is started shortly before transplanta-
tion. When given for treatment of an established GVHD, CyA resolved the skin ma-
nifestations during the course of treatment. Nephrotoxicity and hepatotoxicity have 
been problems in several of these patients (Haws et al., 1981; Gluckman et al., 
1981). 
Mechanism of action 
Cyclosporin A acts selectively on T lymphocytes, as is evidenced by both its in vitro 
inhibition of the Con A and PHA induced proliferative response of rat lymphocytes 
(Burckhardt and Guggenheim, 1979) and human lymphocytes (Leapman et al., 
1981) and its failure to suppress antibody synthesis to lipopolysaccharide antigens in 
nude mice (Borel et al., 1977). In general, B lymphocytes are thought not to be sensi-
tive to CyA (Gordon and Singer, 1979). Further, a depletion of cellular elements has 
been seen in those areas of the reticuloendothelial system that are postulated to con-
tain cytotoxic and helper T cells (Baldwin et al., 1981b). 
The drug acts in the early phase of the immune response, although it is active only 
when present at the time of exposure of the recipient to antigen. Studying human 
lymphocytes in culture, it was observed that the drug is rapidly taken up by lympho-
cytes (within a few minutes) and that especially actively proliferating clones are in-
volved; the most striking effect is the inhibition of uridine uptake soon after admi-
nistration (Leoni et al., 1978). When given some time after transplantation, CyA is 
no longer effective in preventing kidneY graft rejection in the rat (Homan et al., 
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1980e) or GVHD in man. 
The initially suggested clonal deletion which would explain the action of CyA has 
been refuted, considering the fact that in outbred species rejection nearly always oc-
curs after discontinuation of the drug (Borleffs et al., 1981; Niessen et al., 1981). 
From experiments in rats, it could be deduced that CyA and enhancing serum opera-
te on the same part of the immune response, because CyA acts synergistically with 
heterologous antilymphocyte serum but not with enhancing antisera (Homan eta!., 
1980b). Several studies support the concept that CyA inhibits the generation of cyto-
toxic T lymphocytes, but not the generation and expression of suppressor T cells 
(Gunn et al., 1980; Leapman et al., 1981). The immune suppression induced by CyA 
might be a reflection of its preventing the generation of cytotoxic T cells, concomi-
tantly allowing the expression of suppressor cells (Hess et al., 1981). The "toleran-
ce" induced by Cy A has been discussed previously. 
In conclusion, it can be stated that CyA is still a very promising immunosuppressant 
and with acceptable side effects. It can be steroid sparing and at least represents an 
alternative to the conventional immunosuppressants used. Its precise action remains 
unknown but it acts in the early phase of the immune response, selectively on proli-
ferating helper or cytotoxic T cells. Its long-term effects will have to be awaited. 
1.3. HISTOCOMPATIBILITY MATCHING 
Many different histocompatibility antigens are expressed on the cells of each indivi-
dual. The strong or major histocompatibility antigens on donor cells are more likely 
to evoke a rejection reaction in the recipient than weak or minor histocompatibility 
antigens. The genetic codes for the strong transplantation antigens that form the 
major histocompatibility system are clustered on a particular chromosomal region; 
genes of this specific chromosomal region make up what is called the Major Histo-
compatibility Complex (MHC) and such a complex has been defined in many spe-
cies (Gotze, 1977). In man, the MHC is located on the sixth chromosome. Its pro-
ducts can be detected on leukocytes by serological methods or by the mixed lympho-
cyte reaction (see Materials and Methods). The MHC in man has been designated as 
HLA (human leukocyte antigens) (Bach and van Rood, 1976) and that in the dog as 
DLA (dog leukocyte antigens) (Vriesendorp, 1980). Tissue typing makes possible 
the choice of donors that are more compatible with the recipient than are random 
individuals. 
Ideally, a perfect match should allow for a significant increase in graft survival; ho-
wever, in cadaver kidney grafting, this improvement in graft survival following 
HLA-A, -B matching is on the average not more than 10-15"1o at one year between 
the poorest and the best matched groups (Morris, 1981a). Only two centres have re-
ported a greater benefit of matching (van Hooff et al., 1974; Festenstein et al., 
1976). The relative value of HLA-A, -B matching in cadaveric kidney transplantati-
on has also been confirmed by the multicentre prospective data presented at the 
Eighth Histocompatibility Workshop (Opelz and Terasaki, 1980b). 
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Better results can probably be obtained by matching for DR antigens (van Rood 
et al., 1979a, 1979b, 1981; Ting and Morris, 1981). DR antigens can be serologically 
determined; their name refers to the fact that these B-cell antigens -which are be-
lieved to be analogous to the murine Ia antigens - are closely associated with the D 
locus antigens. B-cell antigens are controlled by the chromosomal D region in man 
and could be defined only by the mixed lymphocyte reaction until four years ago. 
The possibility of using serological techniques instead of the relatively cumbersome 
cellular ones made prospective matching forD locus antigens clinically practical. It 
has not yet been fully clarified whether D and DR antigens are products of the same 
locus (Bainer, 1979). Apart from the fact that DR matching seems to be more effec-
tive than matching for HLA-A, -B and -C, it is also more useful because of the 
restricted polymorphism of the DR locus, which exhibits only 7 allelic antigens, whi-
le the A series includes 17, the B series 27, the C series 6 and the MLR defined D se-
ries 11 antigens so far known. The effects of matching for HLA-DR can probably 
be increased by HLA-A and -B matching (van Rood et al., 1981); the results of mat-
ching for HLA-DR and for HLA-A, -B seem to be quite independent. However, the 
results of the Eighth International Workshop Study (Opelz and Terasaki, 1980b) 
still leave some doubts as to the influence of DR matching on graft outcome; there-
trospective data of the Study in particular showed superior results. In the latter stu-
dy, a remarkable correlation between HLA-DR matching and second transplant 
survival was found. Matching for HLA-A and -B loci was found to be not, or only 
marginally, significant in second cadaver transplants (Opelz, 1978; Opelz and Tera-
saki, 1978). 
Within families, histocompatibility matching is of great importance and has been 
shown to be very effective from the beginning (Singal et al., 1969). Especially grafts 
between HLA-identical siblings show very favourable results: about 80 percent of 
grafts will still be functioning after 5 years (Caine, 1980b). Obviously, matching for 
loci other than those on the MHC circumvents the effect of responsiveness towards 
many other unknown incompatibilities. 
Besides a prolonging effect on graft survival, HLA-A, -B matching probably also 
influences patient survival indirectly. It was found in a collaborative analysis of Eu-
rotransplant and the European Dialysis and Transplant Association that HLA-A, -
B matching had a significant influence on patient survival (van Rood et al., 1979b). 
This finding has been attributed to the lesser amount of immunosuppressants requi-
red ro combat rejection crises when donor and recipient are well matched. This 
could be deduced from the correlation between the number of mismatches and the 
number of rejection crisis treatments given. 
Although minor antigens also play a role in graft rejection, relatively little is known 
about the several minor histocompatibility systems. The ABO group antigens, for 
example, are minor antigens. Their effect is relatively well documented; they have 
been shown to shorten allograft survival time in cases of incompatibility (Dausset 
and Rapaport, 1966). At present, donor recipient matching always involves mat-
ching for the blood group antigens. Other minor systems that can influence graft 
survival are the Rhesus blood group (Rh) system, the Lewis blood group system (Fi-
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scher et al., 1979) and a recently discovered system of endothelium/monocyte anti-
gens (Baldwin et al., 1981a). The data of the International Workshop Study (Opelz 
and Terasaki, l980b) surprisingly showed a cumulative effect on the simultaneous 
presence of several red cell mismatches, resulting in decreased graft survival time. 
This observation stresses the possible importance of these minor systems. 
It will be necessary to study the minor systems more extensively to confirm the preli-
minary data obtained. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. KIDNEY TRANSPLANTATION EXPERIMENTS IN DOGS 
Animals 
Beagle dogs were obtained from the Centraal Proefdierenbedrijf TNO, Austerlitz, 
The Netherlands. The beagles were 8 to 12 months of age and weighed 10 to 15 kg. 
Female beagle dogs had not previously been pregnant. Mongrels were obtained 
from local dog handlers via the Centraal Proefdierenbedrijf of the Erasmus Univer-
sity, Rotterdam. They were of approximately the same size and weight as the beag-
les. For female mongrels, no specific information as to previous pregnancies was 
available. 
For the experiments on the effect of matched beagle blood, non-littermate beagles 
of the appropriate tissue type were used as blood donors. Nine unrelated tissue-
typed mongrels were used as third party blood donors. They were selected for nega-
tivity for dog erythrocyte antigens DEA-l and DEA-2 to avoid transfusion reactions 
which have been reported to occur when there were incompatibilities for these anti-
gens (Swisher and Young, 1961). 
Histocompatibility testing 
Histocompatibility testing was performed by serological techniques as well as by the 
mixed lymphocyte reaction (MLR). 
By serologic testing, the serologically defined (SD) dog leukocyte antigens of the 
major histocompatibility complex (MHC), called DLA in the dog, can be detected. 
For this testing, the one- and two- stage microlymphocytotoxicity tests were used to 
determine the cytotoxic activity of a panel of test sera towards the blood lymphocy-
tes of a given individual. In the one-stage test, the donor lymphocytes are suspended 
in complement and are added to an equal amount of antiserum and incubated for 30 
minutes at 37°C. In the two-stage test, equal volumes of cells and antiserum are in-
cubated for 30 minutes at 37°C, followed by a second incubation period with com-
plement (Smid-Mercx et al., 1975; Joint report of second international workshop on 
canine immunogenetics, 1976; Vriesendorp et al., 1977). The reproducibility of both 
tests has been between 90"7o and 95 "To. The selection of the test procedure depends 
mainly upon the way the antisera were raised. With the 120 alloantisera on hand in 
our laboratory, the three SD loci, DLA-A, -B and -C and their respective alleles 
(DLA-A: I, 2, 3, 7, 8, 9, 10, blank; DLA-B: 4, 5, 6, 13, blank; DLA-C: 11, 12, R15, 
blank.) could be defined. 
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Lymphocyte defined (LD) antigens of the MHC can be detected by mixed lympho-
cyte reactions (MLR) (Bijnen eta!., 1977; Bijnen, 1978). In the mixed lymphocyte 
culture (MLC), the lymphocytes of two individuals are mixed and under adequate 
culture conditions the responder cells can be stimulated by allogeneic (stimulator) 
lymphocytes to proliferate and thus incorporate radioactive thymidine into their 
DNA. The amount of incorporation was determined at the sixth day of culture. Ma-
ny variables can influence the amount of DNA synthesized (Bijnen et al., 1979). 
Using homozygous typing cells as stimulator cells in unilateral MLC, the presence of 
DLA-0 and -E loci and their alleles* can be detected. For each donor recipient com-
bination, MLR' s were performed as unilateral cultures in both directions in quadru-
plicate at one time. Dogs were only transplanted if they were positive in MLR with 
their donor, which implies mismatching for LD-antigens. 
It is noteworthy that in the dog a high degree of linkage disequilibrium is present 
between the SO alleles of different loci, between SO and LD alleles and between LD 
alleles of different loci. This implies that certain combinations of alleles occur more 
frequently than could be expected on the basis of the population frequencies of the 
independent alleles of linked loci. The phenomenon of high linkage disequilibrium 
in the dog is attributable to the so-called "founder" effect, which means that a few 
ancestors contributed most of the genes to many next generations. For our beagle 
dogs the relationship between SO haplotypes and LD locus antigens is depicted in 
Table 2.1.A. 
Blood transfusions 
For each transfusion, 100 ml citrated blood was administered to the recipient imme-
diately after collection. 
In the experiment studying the effect of the number and timing of transfusions, 
blood was administered 2 weeks preoperatively or peroperatively, as mentioned in 
the respective sections. 
In all other studies, blood transfusions were administered at 4, 3 and 2 weeks before 
transplantation. 
Plasma transfusions 
A volume of plasma equivalent to 100 ml blood and devoid of cells was also admi-
nistered at 4, 3 and 2 weeks before transplantation. The blood from which the 
plasma was prepared was obtained from the same mongrel donors that were used 
for the fresh whole blood transfusions. The plasma was prepared by centrifugation 
of the blood at 1400 g for 20 minutes. It was stored for several days at a temperature 
of -70'C before administration. 
• 50, 51, 52, 53, 54, 55, 56, 57, 58, R, R, R, R, blank; these alleles cannot yet be 1 2 3 4 
allocated to either locus. 
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The plasma thus obtained is identical to the fresh frozen plasma in common clinical 
use; it contains less than 5 "'o of the blood platelets present in the original amount of 
blood. 
Kidney transplantation 
Renal allografting was performed in a routine manner under ethrane anaesthesia as 
described elsewhere (Bijnen and Obertop, 1980). Kidneys were always placed in the 
iliac fossa of the recipient. The renal artery was anastomosed end-to-end to the ex-
ternal iliac artery and the renal vein was anastomosed end-to-side to the common ili-
ac vein. In case of the presence of a second renal artery, the recipient tail artery was 
used for a second end-to-end anastomosis or the donor was sacrificed and an aortic 
(Carrel) patch was taken which was then sutured end-to-side to the external iliac ar-
tery. The ureter was implanted into the base of the urinary bladder with a submu-
scosal tunnel. 
After removal of the transplant, it was perfused with cold (4°C) 0.9% saline to 
which heparin, 5000 IU/1, and procaine, 2 mg/1, were added. Ischemia times ranged 
from 15 to 35 minutes. Before the skin incision was made, all dogs received 375.000 
IU procaine penicillin and 625 mg dihydrostreptomycin i.m.; this was repeated two 
days after transplantation. Bilateral nephrectomy of the recipient was always per-
formed at the same operation. Parenteral fluid (4.5% saline and 2.5"1o glucose) was 
administered on the day of transplantation and on the first postoperative day. 
Table 2.l.A. SD haplotypes and linked LD locus antigens. 
SD haplotype LD antigen 
2, 4, II so 
2, 5, II 51 
9, 6, 12 52 
3, II 53 
10, 5 54 
3, . 55 
I, 13 56 
7, 5 57 
9, 4, 12 58 
·, 13 57/59 
7, 13 RF 
7, . R2 (R2A, R2B) 
2, 13 R3 
3, 10 R4 
3, 4 R5 
5, II, R20 R6 
10, 4 R7 
LD locus antigens are indicated by the rank number of the homozygous typing cells, with which they were 
determined. 
* Rrefers to the fact that these antigens were discovered in Rotterdam and have not yet been approved at 
an official workshop 
Fig. 2.1.1. Triplet model. C: mongrel; A and B: beagles 
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Postoperative immunosuppression 
Azathioprine (lmuranR, kindly provided by Wellcome Nederland BV) was used at a 
concentration of 10 mg/ml. It was dissolved in saline and titrated with NaOH to a 
PH of 10. 
Prednisolone (Di-adreson-F-aquosum; Organon, Oss, The Netherlands) was used at 
the standard concentration of 25 mg/ml. It was dissolved in distilled water. 
Both azathioprine and prednisolone (Aza/Pred) were administered by daily i. v. in-
jection in doses of 2 mg/kg body weight and l mg/kg body weight respectively, star-
ting on the day of operation. This medication was continued until day 65; thereaf-
ter, it was gradually tapered off during another 50 days, according to the following 
schedule: 
Until day 65 starting dose of both drugs 
From day 65 to 72 : 2/3 x starting dose of both drugs 
From day 72 to 93 : l /3 x starting dose of both drugs 
From day 93 to 105 : 1/6 x starting dose of both drugs 
Routinely, azathioprine was temporarily withdrawn when the leukocyte count drop-
ped to below 3 x 10' /1. 
Cyclosporin A (CyA, kindly provided by Sandoz Ltd., Basle, Switzerland) was sup-
plied as a white powder. For intramuscular injection, it was dissolved in Migyol812R 
(Dynamit Nobel AG; Troisdorf-Oberlar, W-Germany) and absolute ethanol 
(400Jo v /v) by stirring at a temperature of 50°C for 2 hours. For oral administration, 
it was dissolved in olive oil by stirring at a temperature of 60°C for 2 hours. CyA 
was given in daily doses of 2, 5, 10, 15 and 25 mg/kg body weight for 28 days, star-
ting on the day of operation. During the first 4 days after operation, it was admi-
nistered by intramuscular injection in the hind legs in volumes of 0.5- 3.5 ml and by 
oral gavage thereafter. 
Postoperative follow-up 
Serum creatinine levels were determined daily during the first postoperative week 
and at least biweekly thereafter. If the levels increased to above 1000 I' mole/!, the 
dogs were killed. The postoperative day on which the animal died from rejection or 
on which the serum creatinine level exceeded 1000 I' mole/! was taken as the end-
point of graft survival. 
Leukocyte counts were regularly performed; if these dropped to below 3 x 109/1, 
azathioprine administration was temporarily discontinued. 
In the studies using Cy A, serum levels of alkaline phosphatase and aspartate amino-
transferase were also determined to detect possible hepatotoxicity. 
Histopathology 
A postmortem was always performed. Kidney specimens stained with hematoxylin 
and eosin were microscopically examined to confirm the diagnosis of rejection, to 
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score the histological severity of rejection and to check for concomitant disease. 
In the studies using Cy A, liver specimens were also examined microscopically for 
signs of cholestasis. Nonimmunological graft failures were excluded from the study. 
If other organs were found to be diseased at autopsy, samples were taken. 
Experimental design 
The kidney transplantion experiments described in this thesis were always perfor-
med in a triplet model. The kidneys of a nonrelated mongrel donor were transplan-
ted to two beagle recipients and a kidney from one of the beagles was transplanted 
to the mongrel (Fig. 2.1.1). 
In the studies using CyA for postoperative immunosuppression, the beagle reci-
pients were often DLA-identical sibs. In an outbred species like the dog, the existen-
ce of sibs, carrying the same transplantation antigens offers the most sensitive con-
trol group possible for any treatment in transplantation experiments. If the two 
beagles in a triplet are DLA-identical sibs, a difference in graft survival will most li-
kely be the result of a difference in treatment. The treatment under study in our ex-
periments using DLA-identical littermate pairs was the administration of blood 
transfusions. 
Statistical evaluation 
Unless stated otherwise, the Wilcoxon-rank sum test was used. 
A 
c 
B 
Fig. 2.1.1. Triplet model. C, mongrel; A and B, beagles 
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2.2. HEART TRANSPLANTATION EXPERIMENTS IN RATS 
Rats 
Adult male inbred rats of the WAG/Ro (RT I") and BN/Ro (RT I') strains and 
weighing 250-300 g, were used as both donors and recipients of pretransplant blood 
transfusions and cardiac allografts. The animals were obtained from the Centraal 
Proefdierenbedrijf of the Erasmus University, Rotterdam, The Netherlands. 
Blood transfusions 
Blood was obtained from the donor animal by cardiac puncture. Recipients received 
I ml of the citrated blood intravenously 7 days before heart transplantation. 
Heart transplantation 
Intra-abdominal auxiliary heart transplantation was performed according to the 
method described by Abbott and Lindsey (1964). Briefly, the ascending aorta of the 
donor heart was sutured end-to-side to the recipient's abdominal aorta, thus allo-
wing a coronary perfusion of the graft; similarly, the pulmonary artery was sutured 
end-to-side to the inferior vena cava with 7-0 silk. Caval veins and pulmonary veins 
of the donor heart were ligated. The transplanted heart was finally covered with pe-
ritoneum. Rejection was defined as the cessation of palpable heart beats. 
Postoperative immunosuppression 
Only CyA was used for postoperative immunosuppression. It was dissolved in olive 
oil by continuous stirring at a temperature of 60'C for 2 hours. The solution was in-
jected intramuscularly in the hind legs of the rats in volumes of 0.25-0.5 mi. Con-
trols were injected with the same volume of olive oil. 
The drug was administered for 7 days starting on the day of operation in doses of 5, 
10 and 15 mg/kg body weight. 
Histopathology 
A postmortem was always performed. Histological preparations of the grafts stai-
ned with hematoxylin and eosin were microscopically examined to confirm the diag-
nosis of rejection. Nonimmunological graft failures were excluded from the study. 
Animals with concomitant disease as revealed at autopsy were also excluded from 
the study. 
36 
CHAPTER3 
THE EFFECT OF V ARlO US ?RETRANSPLANT TRANSFUSION PROTOCOLS 
ON CANINE KIDNEY GRAFT SURVIVAL 
Though it is generally accepted that pretransplant blood transfusions have a benefi-
cial effect on renal allograft survival the following unsolved questions still remain. 
The effect of blood transfusions per se, without the usual postoperative immuno-
suppressive treatment consisting of azathioprine and prednisolone has not yet been 
evaluated. Of course it would not be ethical to test this in the clinical situation, but it 
should be studied in a well defined preclinical model. 
There have been conflicting reports regarding the optimal number and the timing 
of blood transfusions; these items also await further evaluation. 
Except for improved graft survival blood transfusions can also cause sensitization 
of a future kidney transplant recipient. Therefore it seemed logical to gain the maxi-
mal benefit from a deliberate transfusion policy by administering blood from well 
matched donors, thus maximally avoiding the risk of sensitization. 
Further the effect of the different blood components remains controversial with 
regard to the questions of both sensitization and the effectiveness in prolonging 
graft survival; some blood components have not yet been evaluated in this context, 
e.g., fresh frozen plasma. 
Before a deliberate blood transfusion policy can be recommended, consensus has 
to be reached on the effectiveness and inherent risks of a particular blood transfusi-
on protocol. The present studies in dogs are an attempt to provide answers to these 
questions. 
3.1. THE EFFECT OF THIRD-PARTY BLOOD TRANSFUSIONS WITHOUT 
POSTOPERATIVE IMMUNOSUPPRESSION 
Introduction 
Blood transfusions represent the most important variable improving graft outcome 
in human cadaveric kidney transplantation (Opelz and Terasaki, 1980a). It has been 
demonstrated that third-party blood transfusions also have a significant effect on 
graft survival in dogs receiving Aza/Pred for postoperative immunosuppression 
(Obertop et al., 1978b, Fabre et al., 1978). The use of third-party transfusions best 
mimics the clinical situation in cadaveric kidney transplantation, where recipients 
are transfused with blood from different third-party individuals. This transfusion 
effect has been proved to be very reproducible in our dog model using beagles as re-
cipients and mongrels as kidney donors (Obertop et al., 1979; Bijnen et al., 1982). 
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In a previous communication from this laboratory, it was reported that repeated ad-
ministration of pooled third-party blood did not result in prolonged renal allograft 
survival in nonimmunosuppressed beagle recipients (Bullet a!., 1978). 
It remained to be established, however, whether random third-party mongrel blood 
transfusions would have an effect on renal allograft survival in nonimmunosuppres·· 
sed recipients. As it would be unethical to test this in humans, our dog model see-
med very suitable for further evaluation of the blood transfusion effect in view of 
the reproducible effects obtained. 
In the present study the same protocol was used as described previously (Obertop et 
al., 1978b) (see Materials and Methods), without administration of postoperative 
immunosuppression; this makes the current results comparable to Obertop's study. 
Recipients were transplanted irrespective of a positive crossmatch test. Nontransfu-
sed nonimmunosuppressed dogs, which received a mismatched kidney were used as 
controls. 
Results 
The survival times of the transfused and nontransfused dogs are graphically shown 
in Fig. 3.1.!. The individual survival times and the crossmatch data are given separa-
tely in Table 3.l.A. It is evident that third-party blood transfusions have no effect 
on graft survival in nonimmunosuppressed recipients. The number of transfused 
dogs in this series is too small to allow an evaluation of a possible relation between a 
positive crossmatch test and graft survival. 
Discussion 
From the presented data, it can be concluded that pretransplant third-party blood 
transfusions have no effect on graft survival when compared with nontransfused 
controls. Obviously, the effect of blood transfusions alone on the immune response 
is not sufficient to cause prolonged kidney allograft survival. 
With regard to the immune suppressive effect of third-party blood pretreatment, the 
findings of this study bear a close resemblance to previous active enhancement stu-
dies in the dog. Attempting to obtain prolonged renal allograft survival, Zimmer-
man et al. (1968) pretreated mongrel dogs with repeated injections of subcellular do-
nor antigen without immunosuppression; no significant prolongation of graft survi-
val was found, although a tendency for longer survival was noted. Modifying the 
dosage or duration of antigen administration merely resulted in worsening of the re-
sults but not in prolonged survival. Wilson et a!. (1969) did a similar experiment 
with postoperative administration of Aza/Pred;. they found a very significant pro-
longation of graft survival. Also Jeekel et al. (1975) could not demonstrate a signifi-
cant improvement of kidney graft survival studying both passive and active enhan-
cement in the dog without postoperative immunosuppression. Our data for third-
party blood transfusions are in accord with these findings with regard to the necessi-
ty of immunosuppression to obtain prolongation of graft survival. When postopera-
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Fig. 3.1.1. Kidney graft survival in transfused and nontransfused dogs without postoperative immuno-
suppressive treatment. Transfusions consisted of random third-party mongrel blood. 
Table 3.l.A. Survival times (days) of dogs depicted in Fig. 3.1.1. 
Transfusions 7ND g+ 8ND 
9+ 9+ 12 
No transfusions 7 7 8 
8 9 9 
12 12 12 
14 19 
+ : positive crossmatch test (one- or two-stage microlymphocytotoxicity test) 
ND: crossmatch tests not done 
8 
25 
8 
10 
13 
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tive immunosuppression is given it does not seem to matter whether repeated pooled 
blood transfusions or random third-party transfusions are administered. For, as 
mentioned above, repeated pooled blood transfusions without postoperative immu-
nosuppression did not result in significantly prolonged graft survival (Bull et a!., 
1978); however, it was found in another study that addition of posttransplant im-
munosuppressive treatment resulted in the beneficial blood transfusion effect beco-
ming manifest (Abouna eta!., 1977). 
It seems that, in outbred animals such as dogs, postoperative immunosuppression is 
required for the expression of a beneficial effect induced by third-party or donor-
specific antigen pretreatment. However, not all authors have unequivocally found 
similar results: Caine eta!. (1966) failed to demonstrate any prolongation of canine 
renal allograft survival using third-party blood and different forms of donor anti-
gen, whether immunosuppressants were or were not used. 
Many protocols designed to obtain prolonged allograft survival in out bred animals 
were adapted from studies in rats to serve as a preclinical model. In inbred rat 
strains, immunosuppression is not required to obtain prolongation of graft survival 
in different active enhancement protocols (Stuart eta!., 1968; Nelson, 1961; Mar-
que!, 1978; Fabre, 1980). The same applies to the effect of blood transfusions. In 
the rat, only donor-specific transfusions are effective (Marque! et al., 1971, 1973; 
Fabre and Morris, 1972) and immunosuppression is not necessary to obtain prolon-
ged graft survival. Third-party transfusions in dogs exert an effect only when follo-
wed by posttransplant immunosuppression. Donor blood transfusions in these ani-
mals have not been proved to be effective without postoperative immunosuppressi-
on (Obertop et al., 1975; Sutherland et al., 1979); however, studies on the effect of 
pretransplant donor blood transfusions in immunosuppressed dog recipients have 
not been reported. The study of Halasz et al. (1964) should not be taken into ac-
count because two separate studies using tissue-typed dogs could not confirm their 
finding that subcutaneous administration of donor blood gave prolonged kidney al-
lograft survival in nonimmunosuppressed mongrel recipients (Obertop et al., 1978a; 
Sutherland eta!., 1979). It is also known that the method of administration may be 
critical in enhancement: subcutaneous antigen administration often results in accele-
rated rejection. 
Although there is a close resemblance between the findings from clinical studies and 
preclinical dog models regarding the effect of blood transfusions, the question arises 
as to whether pretransplant blood transfusions in themselves might influence graft 
survival in the clinical situation. As opposed to the dog recipients in this study, pa-
tients who are eligible for transplantation are nearly always more or less uremic and 
on maintenance dialysis treatment. The diminished immune reponsiveness accom-
panying the uremic state might make the effect of pretransplant transfusions more 
pronounced. An indication for the influence of the pretransplant immunosuppres-
sed state on the expression of the transfusion effect can probably be found in the cli-
nical and experimental survival data after a single transfusion. The effectiveness of 
one pretransplant transfusion seems variable in different centres but can be determi-
ned in multicentre data (Opelz and Terasaki, 1980a); very high one-year survival ra-
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tes amounting to 80 percent have been reported only from some transplantation cen-
tres (Persijn eta!., 1977, 1979; Williams eta!., 1979) and may be the result of a bet-
ter posttransplant follow-up (Opelz and Persijn, 1981). In the dog model, a single 
transfusion did not appear to be effecttive (Obertop et al., 1981) unless pre-
transplant immunosuppression was concomitantly given (van der Linden et al., 
1982). It may be that the effect of only one transfusion is rather weak; however, it 
can be made more pronounced by pretransplant immunosuppression. The above 
reasoning concerning the importance of a pretransplant immunosuppressed state, 
remains a matter of speculation but is of interest with respect to the mechanisms in-
volved. 
In conclusion, it does not seem justified to treat patients with only pretransplant 
blood transfusions and not with postoperative immunosuppressants. 
3.2. THE EFFECT OF NUMBER AND TIMING OF THIRD-PARTY BLOOD 
TRANSFUSIONS 
Introduction 
Blood transfusion has been shown to be the most consistent and most dominant va-
riable influencing renal allograft survival (Opelz and Terasaki, 1980a; Spees et al., 
1980). It seems unethical nowadays to withold blood transfusions from prospective 
transplant recipients and consequently many transplantation centres have changed 
their formerly rather restrictive transfusion policies. The inherent risks of transfusi-
ons consist of the sensitization of future recipients and the transmission of infecti-
ons such as hepatitis B. These risks increase with the number of transfusions (Opelz 
et al., 198lc; Fehrman et al., 1980). Although the benefit of transfusions may large-
ly outweigh the risk of inducing broadly reactive lymphocytotoxic antibodies, a 
transfusion policy that achieves an optimal protective effect without incurring the 
above-mentioned risks should be developed. Therefore, it seems logical to admi-
nister the minimal number of transfusions evoking a maximal effect. 
No consensus has yet been reached as to the optimal number of transfusions. In 
both retrospective and prospective studies, Opelz and Terasaki (1978, 1979a, 1980a, 
1980b) consistently found a dose-response relationship, i.e., the beneficial effect of 
blood transfusions increases with the number administered; this has been confirmed 
by others (Fehrman et al., 1980; Spees et al., 1980). In their multicentre analysis, 
Opelz and Terasaki (1980a) also found an effect of a single pretransplant transfusi-
on, but only if packed cells were administered. Several authors, mainly reporting re-
trospective single centre analyses, found that about five transfusions was the opti-
mal number to be administered to obtain improvement of graft survival; more 
transfusions often gave no additional benefit (Werner-Favre et al., 1979; Feduska et 
al., 1979; Hourmant et al., 1979; Corry et al., 1980). Only two communications ha-
ve reported an extremely high one-year graft survival ( ± 80"7o) after only one pre-
transplant transfusion (Persijn eta!., 1977; Williams et al., 1979). Because of the wi-
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de variation in findings and opinions, it is of interest to evaluate the effect of a sing-
le pretransplant transfusion in an established preclinical model. Both the graft pro-
tective effect and the frequency of sensitization can be considered. 
An even more certain way to prevent recipient sensitization would be the admi-
nistration of blood during transplantation, provided, of course, that peroperative 
transfusions also improve allograft survival. Stiller et al. (1978) initially reported a 
beneficial effect of peroperative transfusions in a small retrospective study. Many 
reports soon followed from other centres, both confirming (Hunsicker et al., 1980; 
Williams et al., 1980; Rashid and Sengar, 1978) and refuting (Brynger et al., 1978; 
Salaman, 1978; Persijn and van Rood, 1978; Opelz and Terasaki, 1981) that report. 
Recently, Stiller et al. could no longer confirm their initial findings in a subsequent 
prospective trial (Opelz and Persijn, 1980). In summary, it can be said that the effect 
of peroperative transfusions in man is, at the least, controversial. The beneficial ef-
fects of both a single pretransplant transfusion and a peroperative one have been de-
monstrated in the rhesus monkey (vanEs et al., 1978) and in the dog (van der Lin-
den et al., 1982). 
The contradictory findings hitherto prompted us to investigate both questions in 
our dog model using beagles and mongrels. The beagles received one pretransplant 
blood transfusion four weeks or two weeks before operation. Mongrels received one 
blood transfusion during operation. Kidneys were exchanged between mongrels and 
beagles. A standard regimen of Aza/Pred was given postoperatively. Nontransfused 
immunosuppessed dogs which received a MLC mismatched kidney were considered 
suitable as controls. Recipient sera were not screened for lymphocytotoxic antibo-
Table 3 .2.A. Survival times (days) of immunosuppressed (Aza/Pred) dogs which received one pretrans-
plant, one peroperative or no blood transfusion 
1 Preoperative transfusion (-2 weeks) 9 14+ 14 
16+ 42 + 55 
(-4 weeks) 19+ 19ND 54ND 
1 Peroperative transfusion 12 12 16 
No transfusion (controls) 9 10 II 
12 12 12 
15 15 16 
19 19 19 
21 23 26 
35 41 48 
>463 
+ : positive crossmatcn rest (one- or two-stage microlymphocytotoxicity test) 
ND: crossmatch tests not done 
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16 
12 
13 
16 
20 
30 
110 
dies but one- and two-stage crossmatch tests were performed to check for possible 
sensitization. In earlier experiments, a good correlation was found between positive 
crossmatch tests and the presence of lymphocytotoxic antibodies in recipient serum 
(Obertop eta!., 1979). Transfused dogs exhibiting a positive crossmatch test nearly 
always had broadly reactive antibodies (A.M. Dekkers-Bijma, personal communi-
cation). Kidneys were transplanted irrespective of the outcome of the crossmatch 
tests. 
Results 
The survival times of the experimental groups and the crossmatch data are given in 
Table 3.2.A. 
The survival times of the transfused groups were not significantly different from the 
controls. Crossmatch tests were done for 9 of II preoperatively transfused reci-
pients; 6 of these 9 dogs showed a positive test. Positive crossmatches were not cor-
related with altered graft survival. 
Discussion 
In this study neither one pretransplant transfusion nor one peroperative transfusion 
exerted an improving effect on graft survival. Also in the dog model, van der Linden 
et a!. (1982) found an effect of one peroperative whole blood transfusion, whereas 
one pretransplant transfusion was shown to be only marginally effective with con-
current pretransplant immunosuppression. 
Considering the absence of a peroperative transfusion effect in our study, it should 
be taken into account that an unexpected variable may have been introduced by 
transplantation of kidneys from transfused donors. It has been reported that trans-
fusions to the donor shortly before transplantation reduced renal allograft survival 
in the dog (Jeekel eta!., 1980). It remains to be determined to what extent earlier 
transfusions to the donor influence renal allograft survival. 
The fact that one pretransplant or peroperative transfusion had no improvement ef-
fect is also at variance with the monkey data (vanEs eta!., 1978). In mismatched 
rhesus monkeys, one pretransplant blood transfusion caused both prolonged and 
accelerated rejection. The accelerated rejection could not be foreseen because con-
ventional serological tests did not reveal sensitization. Recipients transfused during 
or shortly before transplantation almost uniformly exhibited prolonged survival of 
approximately the same duration. This improvement was less than after five trans-
fusions. In rhesus monkeys, the beneficial effect obviously increases with the num-
ber of transfusions, as has also been described by Opelz and Terasaki (1980a) for the 
clinical situation. This dose-effect probably also exists in dogs, but the threshold 
may lie at a different level. This could be deduced from the earlier observations 
(Obertop eta!., 1978b) that three transfusions caused markedly prolonged survival 
())60 days) in 6 of 10 recipients; however, there is no information on the effect of 
more transfusions in immunosuppressed dogs. 
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The reasoning that one transfusion should be safer from the viewpoint of sensiti-
zation does not appear to be true. After one pretransplant transfusion, two-thirds of 
recipients exhibited a positive crossmatch, which is a good measure for broad sensi-
tization. In a compilation of dogs from recent foregoing studies, approximately 
401l!o showed a positive crossmatch following three transfusions (unpublished obser-
vations). The finding of a greater number of sensitized recipients after one transfusi-
on may be explained by the fact that a loss of antibody reactivity can occur in spite 
of repeated additional transfusions. This phenomenon has been reported by Opelz 
et al. (1973b) and has been subsequently confirmed in a prospective study with hu-
man volunteers by Ferrara et al. (1974), but in a donor-specific situation. Patients 
who showed such a loss of antibody reactivity had a better graft survival than non-
sensitized ones, which seems indicative for a special state of unresponsiveness 
(Opelz et al., 1981a). This phenomenon could also be observed in our dog model 
(Obertop et al., 1978b), where a decrease in immune (antibody) reactivity in some 
animals receiving three intermittent pretransplant transfusions was shown. Also in 
that study loss of antibody reactivity was correlated with markedly prolonged graft 
survival in all cases. 
Because one preoperative transfusion led to no significant improvement in dogs, 
the possible effect of the time interval between the last transfusion and transplanta-
tion cannot be properly evaluated. When three transfusions were given four, three 
and two weeks before transplantation, a strongly positive effect was seen, while one 
transfusion at four or two weeks pretransplant gave no prolonged survival. Opelz 
and Terasaki (!980b) could not report an effect of the time interval between transfu-
sion and transplantation from the prospective data of the International Workshop 
Study; this interval was found to be inversely related to the number of transfusions. 
Thus, a beneficial effect of transfusions shortly before operation merely reflects the 
effect of an increasing number. 
Theoretically, this interval might be important when proposed mechanisms for the 
transfusion effect are considered. Several studies in man (Fischer et al., !980; Smith 
et al., !981) and experimental animals (Marquet et al., 1982) suggest that suppressor 
cells play a role. It has been found that suppressor cell activity in man is optimally 
effective three weeks after transfusion and remains present for about five months 
(Smith et al., 1981). This may have implications if only one transfusion is administe-
red within three weeks before transplantation. Yet, the data from the few dogs 
transfused four weeks pretransplant do not support this hypothesis. Also the effect 
of one transfusion administered more than one year before transplantation (Persijn 
et al., 1979) cannot be fully explained by the above-mentioned findings regarding T 
suppressor cells. 
In summary, the findings presented show that one pretransplant transfusion does 
not significantly improve kidney graft survival and do not prove that one transfusi-
on would give less sensitization. On the contrary, when these data are considered in 
connection with Obertop's study, the results are suggestive for a decrease in immune 
reactivity with an increasing number of transfusions. The effect of peroperative 
transfusions is still open to question. 
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3.3. THE EFFECT OF MATCHED BEAGLE BLOOD TRANSFUSIONS WITH 
POSTOPERATIVE ADMINISTRATION OF AZATHIOPRINE AND 
PREDNISOLONE 
Introduction 
The ideal of a clinical transfusion policy remains the achievement of a protective ef-
fect against graft rejection without the risk of sensitization. Sensitization may lead 
to accelerated graft rejection or render patients practically unsuitable as transplan-
tation candidates. Theoretically, sensitization can be prevented as much as possible 
by administering matched blood, i.e., blood exhibiting the same, defined, trans-
plantation antigens as are present on recipient tissue. On the other hand, it is proba-
bly necessary to administer a certain load of different antigens to induce a state of 
unresponsiveness (Fehrman et al., 1980) that is sufficient to have an effect on graft 
survival. Little is known about the effect of matched transfusions. In a preliminary 
report on 10 patients, Nube et al. (1981) showed that two or three HLA-A, -B mat-
ched transfusions had a beneficial effect on graft outcome. However, Albert et al. 
(1981) found that the administration of one or three matched transfusions resulted 
in relatively poor graft survival. In the rhesus monkey, one SD-matched blood 
transfusion resulted in prolonged graft survival in five of seven SD-identical immu-
nosuppressed recipients (vanEs et al., 1978). 
In the present study, an attempt was made to evaluate the effect of matched blood 
transfusions on renal allograft survival in our dog model. 
Experimental Design 
Beagle dogs were used as recipients and mongrels as kidney donors. As in all other 
studies all combinations of kidney donors and recipients were positive in the MLR, 
indicating LD incompatibility (see Materials and Methods). Tissue typed beagle 
dogs were chosen as blood donors and kidney recipients, because many of their 
histocompatibility antigens are defined and their pedigrees are known. 
In the first experiment three mutually DLA- (SD- and LD-) identical blood transfu-
sions from unrelated blood donors were administered to unrelated mutually DLA-
identical kidney recipients (DO) and to unrelated, mutually DLA-identical, kidney 
recipients, which were DLA-mismatched with the blood donors (02). Because of 
the unexpected results of this first experiment a second one was done, involving the 
administration of three mutually mismatched beagle blood transfusions to three un-
related mutually mismatched recipients (02D) (see Table 3.3.A.). In view of the 
restricted variation in MHC antigens and the limited number of dogs(!), it was im-
possible to always administer fully mismatched transfusions to the recipients of 
group 0 2D. In these dogs certain SD antigen haplotypes nearly always occur in 
combination with the same LD antigens as a result of high linkage disequilibrium 
(see Materials and Methods table 2.1.A.). 
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Table 3.3.A. Serological tissue-typing data of beagle recipients and beagle blood donors 
Experimental Dog Recipient Blood donor Survival 
group number DLA-antigens DLA-antigens time (days) 
Group DO 800657 7,-/9,6,12 7,-/9,6,12 9 
7,-/9,6,12 
7,-/9,6,12 
791814 9,6,12/10,4 9,6,12/10,4 12 
9,6,12/10,4 
9,6,12/10,4 
801606 9,6,1211,13 9,6,12/1,13 12 
9,6,12/1,13 
9,6,12/1,13 
801539 9,4,12/3,10 9,4,12/3,10 13 
9,4,12/3,10 
9,4,12/3,10 
791827 9,6,12/1,13 9,6,12/1,13 13 
9,6,12/1,13 
9,6,12/1,13 
801496 7,-/9,6,12 7,-/9,6,12 16 
7,-/9,6,12 
7,-/9,6,12 
791718 7,-/9,6,12 7,-/9,6,12 19 
7,-/9,6,12 
7,-/9,6,12 
8253 9,6,12/1,13 9,6,1211,13 26 
9,6,12/1,13 
9,6,12/1,13 
Group 02 800474 9,4,12/3,10 9,6,12/1,13 10 
9,6,12/1,13 
9,6,12/1,13 
791728 R20,5, 11/2,5,11 7,-/9,6,12 10 
7,-/9,6,12 
7,-/9,6,12 
791719 7,-/9,6,12 9,6,12/1,13 12 
9,6,1211,13 
9,6,12/1,13 
800713 7,-/3,10 9,6,12/4,10 13 
9,6,12/4,10 
9,6,12/4,10 
800716 3,10/10,4 7,-/9,6,12 13 
7,-/9,6,12 
7,-/9,6,12 
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79077I 2,4, Il/9,6,I2 9,4,I2/3,IO I6 
9,4,I2/3,!0 
9,4,I2/3,IO 
79I727 RI0,5, II/9,4, I2 9,6,I2/I,I3 48 
9,6,I2/I,I3 
9,6,I2/I,IJ 
80I538 9,4,I2/3,!0 7 ,-/9,6, I2 54 
7,-/9,6, I2 
7,-/9,6,I2 
Group D2D 800556 5,II,R20/6,IO 5,II,R20/6,10 !0 
6,-/9,4, I2 
4,!017,-
800577 5,ll,R20/6,10 2,4,I1/3,IO I2 
9,4,I211,!3 
9,6,12/2,5,11 
791721 7,-/9,6, 12 7,-/9,4, 12 12 
9,6,12/2,5,II 
I,1317,5 
790893 9,6,12/1,I3 5,ll,R20/6,IO 13 
6,-/9,4, I2 
4,1017,-
800789 2,4,II/7,5 9,6,12/2,5, II I4 
3,!017,5 
1,I3/9,6,12 
80I497 9,6,I2/7,5,R15 9,6,I2/3,10 30 
7,-/9,4, I2 
I,13/9,6,I2 
80I440 6,-/9,4,12 9,6,12/3,10 36 
7,-/9,4,I2 
1,I3/9,6,12 
801707 7,-/9,6,12 9,4,12/3,10 61 
9,4,I2/1,I3 
9,6,12/2,5,11 
791712 7 ,-/9,6, I2 9,6,12/2,5,11 >200 
3,I017,5 
1,I3/9,6,12 
Do three DLA-identical blood transfusions 
02 three DLA-mismatched blood transfusions 
02D three different DLA-mismatched blood transfusions 
NT no transfusion 
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The sera of the transfused recipients were not screened for the presence of cytotoxic 
antibodies; instead one- and two-stage crossmatch tests were performed (see section 
3.2.). Kidneys were transplanted regardless of the outcome of the crossmatch tests. 
All dogs received the standard immunosuppressive treatment of Aza/Pred. 
Results 
The survival times of the three experimental groups are graphically represented in 
Fig. 3.3.!. For comparison, a control group was included, consisting of nontransfu-
sed dogs which were grafted with mismatched kidneys and subsequently treated with 
Aza/Pred. The individual survival times and the crossmatch data are given in Table 
3.3.B. 
No significant difference in graft survival between the three experimental groups 
and the control group was demonstrable. In the groups receiving DLA-mismatched 
blood (D2 and D2D), there seemed to be a slight tendency for longer survival when 
compared with the group receiving DLA-identical blood (DO). Yet no significant 
correlation could be found between the number of mismatched antigens administe-
red and the survival times or between the number of mismatched antigens and the 
occurrence of positive crossmatch tests (see Table 3.3.A.). 
Positive crossmatches occurred in only I of 8 dogs receiving DLA-identical transfu-
sions (DO), in 4 of 8 receiving mutually identical DLA-mismatched transfusions 
(D2) and in 3 of 9 receiving different DLA-mismatched transfusions (D2D). 
Discussion 
In the experiment described in the preceding section (3 .2) the administration of only 
one pretransplant transfusion or of a peroperative one has been discussed as a possi-
ble alternative to obtain a blood transfusion effect without the risk of sensitization. 
Another way to prevent sensitization to a great extent is to avoid a challenge with in-
compatible transplantation antigens by administration of blood from SD- and LD-
identical individuals, i.e., well-matched blood transfusions. Although the underly-
ing mechanism is not fully understood, several findings point to the fact that the 
transfusion effect might be dependent upon the presentation of a sufficient amount 
of antigen. This could be derived from the findings that leukocyte-free blood (Per-
sijn et al., 1979) and also frozen blood in large multicentre studies (Opelz and Tera-
saki, 1978, 1980a) do not seem to induce a prolongation of kidney graft survival, or 
do so to a lesser extent; it has been further demonstrated in several studies that a cer-
tain minimal number of transfusions, e.g., five or more, is optimally effective in ob-
taining a beneficial effect on graft survival. The latter reasoning would imply that 
the administration of matched blood with as few antigenic incompatibilities as pos-
sible might not result in prolongation of graft survival. Thus far, little research has 
been done on this relatively new topic. A preliminary report from the Leiden group 
(Nube et al., 1981), dealing with relatively few patients and using historical controls, 
suggests that HLA-A and -B matched blood can have a prolonging effect on graft 
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Fig. 3 .3.!. Kidney graft survival in immunosuppressed (Aza/Pred) beagles which were transfused with 
beagle blood. 
DO three DLA-identical blood transfusions 
D 2 three DLA-mismatched blood transfusions 
D2D three different DLA-mismatched blood transfusions 
NT No transfusion 
Table 3.3.B Survival times of dogs (days) depicted in Fig. 3.3.!. 
DO DLA-identical transfusions 9 12 12 13 
13 16 19+ 26 
D2 DLA-mismatched transfusions 10 10+ 12+ 13 + 
13 16 48 54 + 
D2D Different DLA-mismatched transfusions 10 12+ 12 13 
14+ 30+ 36 61 
) 100 
NT No transfusions 9 10 11 12 
12 12 12 13 
15 15 16 16 
19 19 19 20 
21 23 26 30 
35 41 48 110 
»463 
+ positive crossmatch test (one- or two-stage micro1ymphocytotox.icity test) 
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outcome which is comparable with the excellent results of one random pretransplant 
transfusion in this centre. The Munich group (Albert et al., 1981), on the other 
hand, has already discontinued this matched-transfusion policy, because in compa-
rison with mismatched transfusions poor allograft survival was observed. On the 
basis of the results obtained with leukocyte-free blood and matched transfusions, 
they concluded that HLA antigens present on leukocytes play a role in the transfusi-
on effect. 
In both studies, the frequency of cytotoxic antibody production seemed to be lower 
than average. In the Leiden study, only two patients exhibited weak cytotoxic anti-
body activity, which was probably directed against HLA-DR antigens, and a third 
one showed a temporary strong anti-HLA-A and -B activity. However, no contem-
porary controls who received mismatched transfusions were available for compari-
son. In the Munich study, antibody production tended to be less but was not signifi-
cantly decreased as compared with the group receiving mismatched transfusions. 
A single SD-matched transfusion caused prolongation of graft survival in the rhesus 
monkey (vanEs et al., 1978); however in that study, kidney donors and recipients 
were also optimally matched for A and B (SD) locus antigens. It was further found 
that five of seven recipients developed cytotoxic antibodies which were not related 
with graft survival. It is therefore difficult to state anything conclusive about the ef-
fect of matched blood tranfusions in considering the above-mentioned data. But the 
impression remains that the decrease in cytotoxic antibody induction mediated by 
this transfusion policy is not a dramatic one. 
Our study in tissue-typed beagles which were transfused with matched beagle 
blood showed quite unexpected results. It was shown in the first experiment that 
three mutually identical transfusions had no significantly different effect in both 
DLA-identical and DLA-mismatched recipients. Because mongrel blood transfusi-
ons had a prolonging effect under the same circumstances, the present findings indi-
cated that the antigenic composition of three identical beagle blood transfusions was 
not suitable for the induction of a transfusion effect. An explanation might be that 
three identical beagle blood transfusions might not offer a sufficiently varied 
amount of antigens and that they were in this sense comparable with only one trans-
fusion, which did not prolong graft survival in our model using standard conventio-
nal immunosuppression postoperatively. However, various differently mismatched 
transfusions also produced no significantly prolonged graft survival. Therefore it is 
a more likely hypothesis that beagle blood lacks the decisive antigens to induce a be-
neficial transfusion effect in beagle recipients. Obviously, the MHC antigenic diffe-
rences for which we can type at present do not play a major role in the induction of a 
blood transfusion effect in this model. Probably undefined, minor histocompability 
antigens or as yet unknown MHC antigens or the combination of several types of 
antigenic differences are required to induce an improved graft survival. The results 
obtained may be best explained by the existence of an in-breeding effect in these 
beagle dogs, which originated also a smaller pool of undefined antigenic differen-
ces. The antigenic substrate seems to be confined to the cellular blood elements (see 
section 3.4). 
50 
In the present study, DLA-identical transfusions indeed caused little sensitization, 
as can be deduced from the number of positive crossmatches. As earlier explained 
(section 3.2), the number of positive crossmatch tests can give an impression of the 
frequency of broadly reactive antibodies. In a compilation of 83 dogs from recent 
previous studies an average percentage of 40"7o positive crossmatch tests was found 
after three third-party blood transfusions. DLA-mismatched beagle blood transfusi-
ons resulted in as many positive crossmatches as did mismatched mongrel blood, in-
dicating that the MHC antigenic differences in beagle blood equally cause sensitiza-
tion. 
Briefly, this study supports the idea that (known) MHC antigenic differences are 
not very important for the induction of the transfusion effect. Furthermore opti-
mally matched beagle blood transfusions indeed seem to induce much less sentitiza-
tion in beagle dogs. 
3.4. THE EFFECT OF THIRD-PARTY PLASMA WITH POSTOPERATIVE 
ADMINISTRATION OF AZATHIOPRINE AND PREDNISOLONE. 
Introduction 
Blood transfusions have a beneficial effect on renal allograft survival. Several blood 
products have already been analysed for their prolonging effect. Leukocyte-free 
blood seems to be ineffective in humans (Persijn eta!., 1979). There have been con-
flicting reports concerning the effect of frozen blood; some publications from single 
centres have claimed a beneficial effect of frozen blood (Polesky, 1977; Fuller, 
1977), whereas Opelz and Terasaki (1974, 1978, 1980a) in their mu1ticentre analysis 
data found that frozen blood is definitely less effective; this was confirmed by the 
prospective data from the International Workshop Study (Opelz and Terasaki, 
1980b). Whole blood, packed cells and washed packed cells all have about the same 
effect (Spees eta!., 1980; Opelz and Terasaki, 1980a). 
In preclinical models, both leukocytes and erythrocytes have been shown to result in 
prolonged graft survival (Obertop eta!., 1979; vanEs eta!., 1978). 
Nothing is known from clinical studies about the effect of plasma transfusions befo-
re transplantation; the same applies to platelets. Plasma and platelets contain HLA 
antigens in soluble and particulate form, respectively (Pellegrino eta!., 1974). Also 
from experimental studies in outbred animals, little is known about the effect of 
pretreatment with third-party plasma on renal allograft survival. Harder et a!. 
(1979) investigated the combined effect of different blood products and donor pre-
treatment on renal allograft survival in dogs. They found that donor blood transfu-
sions, donor plasma transfusions and third-party plasma transfusions were equally 
effective in prolonging kidney graft survival, when combined with preoperative 
nonspecific immunosuppression, but without postoperative immunosuppression. 
In the present study, third-party plasma from three mongrel donors was investiga-
ted for its effect on kidney graft survival in our dog model, employing the same pro-
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tocol that had been used to demonstrate the effect of whole blood, erythrocyte and 
leukocyte transfusions. Plasma was prepared according to the method employed for 
the clinical preparation of fresh frozen plasma (see Materials and Methods). lt was 
administered to the beagle recipients at 4, 3, and 2 weeks before transplantation. 
Aza/Pred were used for postoperative immunosuppression at standard dosages. 
Results 
The survival times of the dogs transfused with plasma are graphically shown in Fig. 
3.4.1. For comparison, we included a control group consisting of nontransfused 
dogs, which were also grafted with mismatched kidneys and subsequently treated 
with conventional immunosuppression; their survival times have been published 
previously (Bijnen et al., 1980). The individual survival times are given in Table 
3 A.A. The dogs transfused with plasma tend to survive for shorter periods than the 
nontransfused controls; however, the difference is not statistically significant. 
All crossmatch tests between recipient sera and donor lymphocytes were negative in 
the experimental group. 
Discussion 
From the results presented, it can be concluded that third-party plasma has no signi-
ficant effect on kidney allograft survival in dogs when conventional immunosup-
pressants are administrered postoperatively. The fresh-frozen plasma used in this 
study contained HLA antigens in both soluble form and rep.esented on platelet 
fragments; only five percent of the platelets present in blood are retained in the 
plasma solution after centrifugation. Obviously, this method of presenting antigens 
does not induce a similar effect as the equivalent amount of whole blood in combi-
nation with postoperative immunosuppression. 
It has been shown by van Rood et al. (1970) that plasma is effective only in a donor-
specific setting and that the effect was dependent upon the composition of the anti-
gen mixture present in the plasma. It was found that donor plasma caused accelera-
ted rejection of a donor skin graft, but not of third-party skin. On the other hand, 
plasma free of platelets and particulate matter caused prolongation of skin allograft 
survival in the donor specific situation. This finding supports the concept that parti-
culate antigens tend to be immunogenic and soluble ones tend to be tolerogenic (Fa-
bre, 1980; Marquet, 1978). Harder et al. (1979) showed that third-party plasma can 
influence renal allograft survival in a beneficial way when preoperative immunosup-
pressive treatment employing procarbazine and antithymocyte serum is given after 
the plasma transfusions. In their dog model, third-party plasma, donor plasma and 
donor blood were equally effective and this suggests that the underlying mechanism 
is not donor specific. Several experiments using donor-specific plasma have been 
performed. Tinbergen (1971) and Jenkins et al. (1971) administered donor strain 
plasma in rat models, which showed no prolongation of allograft survival as oppo-
sed to whole blood. Fagiolo et al. (1979) transfused donor plasma in outbred rab-
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Table 3.4.A. Survival times (days) of dogs depicted in Fig. 3.4.1. 
Plasma transfusions* 8 11 11 13 
13 16 33 
No transfusion 9 10 11 12 
12 12 12 !3 
15 15 16 16 
19 19 19 20 
21 23 26 30 
35 41 48 110 
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.. all crossmatch tests were negative 
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bits; they found a significantly prolonged skin allograft survival, which was even 
more pronounced than the effect of whole blood. Caine et al. (1970) found that pigs 
transfused with donor blood or donor plasma exhibited prolonged kidney graft sur-
vival; they ascribe their finding to the presence of soluble tolerogenic transplantati-
on antigens. The latter experiments were done without postoperative immunosup-
pression. They cannot be compared to our study in dogs using third-party plasma 
and postoperative immunosuppression. Those experiments are more comparable 
with other active enhancement studies that employ donor antigen pretreatment to 
achieve prolonged allograft survival in a donor specific way (Caine eta!., 1970; Wil-
son et al., 1969; Marque!, 1978). In view of the findings of Harder eta!., (1979), it 
remains to be elucidated whether a nonspecific component is involved in the above-
mentioned experiments. 
In our study, there were no positive crossmatch tests following repeated preopera-
tive plasma transfusions. On the average, 40'1o of dogs, which received three blood 
transfusions, have a positive crossmatch against donor lymphocytes (unpublished 
observations). Therefore it does not seem likely that many broadly reactive lympho-
cytotoxins were produced; however, the sera of the transfused dogs have not been 
tested against a panel of lymphocytes. It has been hypothesized that the use of cer-
tain blood derivatives such as the plasma protein fraction might shorten renal allo-
graft survival because of sensitization to HLA antigens (Pattison eta!., 1974). No 
evidence supporting this hypothesis has been reported up to now. 
Pretreatment with third-party plasma in combination with postoperative conven-
tional immunosuppression did not result in prolongation of renal allograft survival. 
To obtain a beneficial effect on graft survival, it might be necessary to add pre-
transplant immunosuppression to the present protocol on the basis of the data of 
Harder eta!. (1979) and the results obtained with one pretransplant transfusion (see 
section 3.2). It was found that one pretransplant transfusion was effective only 
when concomitant pretransplant immunosuppression was given (van der Linden et 
al., 1982). Extrapolating these findings to the clinical situation, pretransplant 
plasma transfusions might have an improving effect on renal allograft survival when 
administered to uremic patients who are known to have a depressed immune respon-
siveness. 
At present, the administration of whole blood remains the most certain and effecti-
ve means to obtain prolonged kidney graft survival. 
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CHAPTER4 
THE EFFECT OF POSTTRANSPLANT ADMINISTRATION OF 
CYCLOSPORIN A ON RAT HEART ALLOGRAFT SURVIVAL IN 
TRANSFUSED AND NONTRANSFUSED RECIPIENTS 
Introduction 
The novel immunosuppressant cylosporinA (CyA) has been shown to be very effec-
tive in suppressing graft rejection, especially in nonsensitized recipients (Brent, 
1980). There is still much debate about its action on the secondary immune response 
(Borel et al., 1977; Brent, 1980; Deeg et al., 1980), which is an important considera-
tion with respect to the possibilities of treatment of sensitized patients. 
In the clinical situation pretransplant third-party (Opelz and Terasaki, 1980a) and 
donor-specific (Salvatierra et al., 1980) blood transfusions given to prospective (ca-
daver) kidney graft recipients may have a beneficial effect on allograft survival. This 
beneficial blood transfusion effect has also been shown in outbred animals such as 
dogs (Obertop et al., 1978b) and monkeys (vanEs et al., 1977) and in inbred rat 
strains (Marque! et al., 1971). However, blood transfusions carry the risk of sensiti-
zation (Patel and Terasaki, 1969) with subsequent poor graft prognosis. In the in-
bred WAG/Ro (RT 1u) and BN/Ro (RT 1n) rat strains a beneficial or deleterious 
effect of pretransplant donor blood transfusions on graft survival can be seen de-
pending upon the donor recipient combination used (Marquet et al., 1971, 1973). 
After conditioning with I donor blood transfusion one week before transplantation 
indefinite survival of a BN/Ro heart allograft is seen in W AG/Ro recipients, whe-
reas accelerated rejection (graft survival 5-6 days) of a W AG/Ro heart occurs in 
BN/Ro recipients. Normally, when nontransfused recipients are involved, each 
strain rejects a heart allograft from the other in 8-9 days. Both pretransplant blood 
transfusions and Cy A are important tools to improve allograft survival. 
It was investigated in this rat model whether postoperative administration of Cy A 
would interfere with the effect of pretransplant blood transfusions in either donor-
recipient combination. 
CyA was administered in doses of 5, 10 and 15 mg/kg during 7 day, starting on the 
day of operation. 
Results 
The survival times of the different experimental groups are shown in Table 4.A. 
In the BN/Ro to WAG/Ro combination, a low dose of 5 mg/kg CyA administe-
red during 7 days was sufficient to give indefinite graft survival in nonsensitized re-
cipients (group 2A). As earlier shown, one blood transfusion led to indefinite graft 
survival in this donor-recipient combination (group 4A). This beneficial transfusion 
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Table 4.A. Rat heart allograft survival in transfused and nontransfused recipients treated with 
cyclosporin A. 
A(BN/Ro to WAG/Ro) B(WAG/Ro to BN/Ro) 
Group Treatment Survival (days) n Survival (days) 
I None 8-9 25 8-9 
2 CyA, 5 mg/kg/day p 8 16, !6, 18, P, P 
3 Cy A, 15 mg/kg/ day 13,28,P,P,P 
4 PBT p 25 5-6 
5 PBT +olive oil p 5 5-6 
6 PBT + CyA, 5 mg/kg/day P 8 2, 3, 4, 4, 6, 7, 9 
7 PBT + Cy A, 10 mg/kg/ day 3, 5, II, 12, 14, 25, 35, 35, 37 
8 PBT+CyA, 15 mg/kg/dayP 7 p 
PBT: pretransplant blood transfusion; P: permanent; CyA: cyclosporin A. 
effect was not affected by any dose of CyA or the solvent (groups SA, 6A, 8A). 
n 
25 
5 
5 
25 
6 
7 
9 
7 
In the WAG/Ro to BN/Ro combination, the low and the high doses of CyA ap-
peared to be almost equally effective in prolonging heart allograft survival in non-
sensitized recipients (groups 2B, 3B). In BN/Ro recipients, transfusion of WAG/Ro 
blood led to sensitization which resulted in accelerated rejection (5-6 days) of 
WAG/Ro hearts (group 4B). In the sensitized BN recipients, a clear dose-effect rela-
tionship for CyA was shown. A dose of 5 mg/kg CyA led to rejection within 4 days 
in about half of the cases (group 6B), whereas the 10 mg/kg dose prolonged allo-
graft survival considerably in most recipients (group 7B). The 15 mg/kg dose of 
CyA abolished the sensitizing effect of a pretransplant blood transfusion (group 8B) 
and resulted in permanent graft survival in all instances. 
From the observations in the W A GIRo to BN/Ro donor-recipient combination, 
it is clear that the dose of CyA needed for prolongation of allograft survival is hig-
her in sensitized recipients than in nonsensitized ones. 
Discussion 
In earlier studies, is was shown that, when administered for a limited period of time, 
CyA can effectively result in long-term renal allograft survival in nonsensitized ro-
dents (Dunn et al., 1980a; Homan et al., 1980e). It has also been reported that CyA 
can prolong cardiac allograft survival in rats, although mostly under continuous 
treatment (Jamieson et al., 1979; Kawahara et al., 1980). 
This study shows that postoperative administration of CyA for 7 days can lead to 
indefinite or prolonged cardiac allograft survival in nonsensitized recipients, depen-
ding upon the donor-recipient combination used. In the weak BN/Ro to WAG/Ro 
combination, a low dose of 5 mg/kg CyA was sufficient to obtain permanent graft 
survival; in the reverse situation a higher dose was needed. This CyA induced phe-
nomenon of permanent organ graft acceptance has been observed only in rodents up 
to now; other mammals reject their transplants after termination of drug admi-
nistration (Caine, 1980a; Niessen et al., 1981). On considering the survival time 
elapsing after discontinuance of CyA treatment in species other than rodents, an a!-
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most normal (control) graft survival is observed in many cases (Homan et al., 1981c; 
Niessen et al., 1981). It seems that these animals react like naive recipients from that 
time on and that CyA only delays the onset of an otherwise normal immune respon-
se. The induction of long or permanent graft survival in rats is not confined to Cy A. 
It has also been observed after administration of other immunosuppressants, such 
as antilymphocyte serum, cyclophosphamide and the combination of azathioprine 
and prednisolone (van Bekkum et al., 1969). 
The data obtained in this study also lend support to the opinion that CyA can act 
as an effective immunosuppressant in sensitized recipients, provided that a suffi-
ciently high dosage is administered. This is in contradiction with an earlier statement 
that CyA might never be effective in sensitized patients (Lindsey et al., 1980). The 
support is especially strengthened by the fact that, in our model, the sensitizing ef-
fect of pretransplant blood transfusions was definitely abolished by an acceptable 
dose of CyA, while the beneficial effect of such pretreatment was unaltered. This 
latter finding might be in accord with the presumed suppressor T cell sparing by 
CyA (Leapman et al., 1980). In the BN/Ro to WAG/Ro donor-recipient combinati-
on, we have evidence that long-term allograft acceptance after the administration of 
a pretransplant blood transfusion is mediated by suppressor T cells (Marquet et al., 
1982). Because the beneficial effect of a pretransplant blood transfusion is not af-
fected by CyA, it is tentative to conclude that CyA does not interfere with the action 
of these suppressor cells. On the other hand, it cannot be excluded that a 5 mg/kg 
dose of CyA even in blood conditioned WAG/Ro recipients is sufficient to cause the 
prolongation of graft survival merely by its immunosuppressive effect, as was obser-
ved in nontransfused recipients in this donor-recipient combination. 
The markedly accelerated rejection observed at the lower dose of CyA in the 
WAG/Ro to BN/Ro donor-recipient combination is difficult to explain. A possible 
explanation may be that it was caused by lgM antibodies. There is suggestive eviden-
ce that CyA acts on T helper cells (Homan et al., 1980e). T helper cells enable the 
shift from IgM to lgG antibody production, especially in a secondary immune 
response. Logically, CyA will suppress this shift and this may lead to a selective pro-
duction of IgM; the latter antibodies have been extensively shown to cause accelera-
ted graft rejection (Mullen et al., 1977). 
In summary, CyA treatment can result in indefinite cardiac allograft survival in 
both sensitized and nonsensitized rats; in the sensitized W AG/Ro to BN/Ro model, 
this effect is dose dependent. This finding is encouraging, since it does not preclude 
the use of CyA in the treatment of sensitized graft recipients. 
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CHAPTERS 
THE EFFECT OF POSTIRANSPLANT ADMINISTRATION OF CYCLOSPORIN 
A ON CANINE KIDNEY GRAFT SURVIVAL IN TRANSFUSED AND 
NONTRANSFUSED RECIPIENTS 
Cyclosporin A (CyA) is probably the most potent single immunosuppressive agent 
known at present (Brent, 1980; Morris, !98lb). Its immunosuppressive action has 
been demonstrated for many different kinds of allografts in a number of species and 
for a variety of antigens. It also effectively suppresses renal allograft rejection in 
man (Caine, 1980a) and in the dog (Caine et al., 1977; Homan et al., !980a). Several 
side effects have been reported in man, in contrast to experimental animals (Caine, 
!980a). Serious, often lethal, infections were observed when CyA was combined 
with other immunosuppressants postoperatively. Some of these side effects are 
clearly dose-dependent, e.g. the nephrotoxic effect. It is still too early to form an 
impression of the long-term effects of CyA. To avoid the occurrence of serious side 
effects, it is desirable to use the minimal dosage of CyA that is required to obtain an 
adequate immunosuppressive effect. Pretransplant blood transfusions have a bene-
ficial effect on renal allograft survival in man (Opelz et al., 1980a); this effect was 
also found in dogs when Aza/Pred were administered postoperatively (Obertop et 
a!., 1978b, 1979). 
It is not known whether an additive or potentiating effect could be achieved by com-
bining the administration of CyA and pretransplant blood transfusions. Yet, in the 
clinical situation CyA is used both in transfused and nontransfused recipients 
(Starzl, 1981a). Therefore it is important to investigate the effect of blood transfusi-
ons in relation to the different immunosuppressants used, CyA in particular. 
In the present studies the effect of CyA was evaluated both as a single agent and 
in combination with conventional immunosuppressants in transfused and nontrans-
fused dogs. Further dose-response studies were done using Cy A in the canine renal 
allograft model; concomitantly the effect of conversion from CyA to Aza/Pred was 
investigated. 
5 .I. THE EFFECT OF CYCLOSPORIN A AS THE ONLY IMMUNOSUPPRESSANT 
IN TRANSFUSED AND NONTRANSFUSED RECIPIENTS 
Introduction 
It is an established fact that pretransplant blood transfusions prolong renal allograft 
survival. However, this has been demonstrated only for transfused recipients who 
received azathioprine and prednisolone postoperatively. Up to now, no communica-
tions have appeared concerning the use of Cy A and pretransplant blood transfusi-
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ons in renal allograft patients. It is important to consider transfusion data when eva-
luating new immunosuppressive drugs, because blood transfusion is the most domi-
nant variable influencing cadaver kidney graft survival (Opelz and Terasaki, l980a; 
Opelz et al., l981a). 
The purpose of the present study was to determine whether a beneficial effect of 
pretransplant third-party blood transfusions would be evident when CyA was admi-
nistered as the only immunosuppressant for 28 days. Since daily doses of 10 to 25 
mg/kg Cy A have already been shown to give very effective immunosuppression in 
dogs (Caine et al., 1977; Homan et al., 1980a), lower doses of CyA were used to al-
low an evaluation of the possible additive beneficial effect of pretransplant blood 
transfusions. 
At operation, two beagles each received a kidney from the same mongrel. Some of 
the beagle pairs (Fig. 5.1.11) consisted of DLA-identicallittermates of the same sex. 
One dog of each pair was transfused. Mongrels were not transfused and received a 
kidney from the nontransfused beagle at the same operation. Kidneys were trans-
planted irrespective of a positive cross match test. Cy A was administered in doses of 
2, 5 and 10 mg/kg/day for 28 days. Control dogs, transfused or nontransfused, also 
received a DLA-mismatched kidney and were not treated postoperatively. Serum le-
vels of creatinine, alkaline phosphatase and aspartate aminotransferase were deter-
mined postoperatively in the CyA treated groups. For the evaluation of liver and 
kidney function under Cy A treatment, only dogs surviving longer than three weeks 
were considered; values were included until rejection was imminent to rule out the 
effect of severe uremia on liver function or the effect of rejection on kidney functi-
on. Leukocyte counts were routinely done. The experimental groups are given in Ta-
ble 5.1.A. 
Results 
The survival times of the dogs are depicted in Fig. 5.l.I; the individual survival ti-
mes and the crossmatch data are given in Table 5.1.A. When the survival times of 
the transfused and the nontransfused recipients are compared, no significant diffe-
rence is demonstrable in any dose group. Comparison of the transfused and non-
transfused sibs of the DLA-identical littermate pairs illustrates in an even better 
controlled way that there is no difference in graft survival (Fig. 5.1.11). 
Dogs treated with Cy A at 5 mg/kg/ day survived significantly longer in both the 
transfused and the nontransfused group. In nontransfused dogs, the 10 mg/kg/day 
dose showed a further improvement in graft survival over the 5 mg dose, which was 
significant (p ( 0.025). In the transfused recipients, this difference was not statisti-
cally significant. Only 5 of 20 recipients in the 5 mg group survived for the duration 
of CyA treatment (28 days), as opposed to 10 of 13 in the 10 mg group. After termi-
nation of CyA treatment, graft rejection always followed. Graft survival after dis-
continuation of Cy A therapy was of about the same duration as for untreated con-
trols. 
No side effects were seen in the CyA treated dogs. 
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Fig. 5.1.1. Kidney graft survival in transfused and nontransfused dogs treated with cyclosporin A in doses 
of 0 (controls), 2, 5 and 10 mg/kg/day. Cyclosporin A was administered for 28 days. 
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Table 5.l.A. Survival times (days) and crossmatch data of dogs depicted in Fig. 
No Immuno~ CyclosporinA CyclosporinA 
Suppression 2 mg/kg 5 mg/kg 
No 7 7 8 8 8 9 12 12 10 12 16 18 
Transfusions 8 9 9 10 19 20 20 21 
12 12 12 13 26 35 60 
14 19 
Transfusions 7ND 8 8ND 8 12 15+ 12+ 13 14 14+ 
9+ 9+ 12 25 16 16+ 40+ 42 
51 
+ 
ND 
positive crossmatch test (one- or two- stage microlymphocytotoxicity test) 
crossmatch tests not done 
survival time 
(days) 
100 
60 
0 2 
D nontransfused 
liD transfused 
5 10 
5.1.1. 
CyclosporinA 
10 mg/kg 
11 33 34 42 
42+ 44 47+ 48 
12+13+37 40 
44 
CyA 
mg/kg/day 
Fig. 5.1.11. Paired comparison of kidney graft survival in transfused and nontransfused DLA-identical 
littermates treated with cyclosporin A postoperatively. Cyclosporin A was administered for 
28 days. 
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Fig. 5.1.111. The effect of different posttransplant immunosuppressive regimens on serum alkaline phos-
phatase levels. Values given are mean values expressed as percentages of preoperative con-
trol levels. The-numbers of dogs considered are given in parentheses. A/P: azathioprine and 
prednisolone; CS: cyclosporin A 5 mg/kg/day; C10: cyclosporin A 10 mg/kg/day. Signifi-
cant differences are indicated (Student's t-test). 
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Fig. S.l.IV. The effect of different posttransplant immunosuppressive regimens on serum aspartate 
transaminase levels. Values given are mean values expressed as percentages of preoperative 
control levels. The numbers of dogs considered are given in parentheses. A/P: azathioprine 
and prednisolone; Cs: cyclosporin A 5 mg/kg/day; CJO: cyclosporin A 10 mg/kg/day. Sig-
nificant differences are indicated (Student's t-test). 
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In the group of transfused dogs, no significant difference in survival was noticeable 
between those showing a positive crossmatch and those which did not. 
On day seven, serum creatinine levels were significantly elevated (p ( 0.05) only in 
the 5 mg group, in comparison with control dogs from a previous study which recei-
ved Aza/Pred (Fig. 5.3.ll). The effect of CyA on kidney function will be more ex-
tensively evaluated and discussed in section 5.3. Serum levels of alkaline phosphata-
se and aspartate aminotransferase are graphically shown in Figs. 5.l.lll and 5.1.IV; 
values expressed are percentages of the preoperative control values. Alkaline phosp-
hatase levels are significantly lower on days five (p ( 0.05) and ten (P ( 0.10) in the 
group treated with 5 mg CyA as compared with control dogs receiving Aza/Pred. 
Serum levels in dogs treated with I 0 mg Cy A were lower than in the Aza/Pred 
group, though not at a significant level. On day 2, serum aspartate aminotransferase 
levels were significantly lower (p ( 0.01) in dogs treated with 5 mg CyA than in tho-
se treated with 10 mg CyA. Normally in nonimmunosuppressed recipients, serum le-
vels of liver enzymes are elevated for about ten days after transplantation, with a 
maximum at two to five days posttransplant (Westbroek, unpublished results). 
No decrease in the leukocyte counts to below the ''critical'' number of 3 .I o9 I I were 
seen in dogs treated with CyA only; count varied from 4.4 to 52 x 109 /I. 
At autopsy, no abnormalities were found except for rejected kidneys, in particular 
no tumours. Histology of the kidney specimens showed that signs of rejection were 
slightly less severe, though mononuclear infiltration was sometimes more pronoun-
ced in dogs receiving CyA only than in those on Aza/Pred or without immunosup-
pression. Liver specimens showed no signs of cholestasis or other specific damage. 
Discussion 
It is apparent from the data presented that CyA does not allow the expression of the 
blood transfusion effect when it is used postoperatively as the only immunosuppres-
sant. This is in contrast with the results obtained when Aza/Pred were used for 
postoperative immunosuppression (Obertop et al., 1978b). It may be argued that an 
administration period of 28 days is a relatively short time for the transfusion effect 
to become manifest. However, this period is long enough to allow a clear dissociati-
on between the survival times of transfused and nontransfused recipients on 
Aza/Pred (80'7o versus 24% respectively). The immunosuppressive dominance of 
CyA does not seem responsible for the absence of the blood transfusion effect. At a 
dose of 5 mg/kg/day, which was even too low for maintenance of the majority of 
the grafts during the course of therapy, no difference in survival time between trans-
fused and non transfused recipients was observed. Obviously, a transfusion effect is 
manifest only when conventional immunosuppressants are used postoperatively. It 
is more likely that the absence of the transfusion effect can be explained by a diffe-
rent interaction between the immunosuppressants used and the immunological me-
chanism that underlies the expression of the transfusion effect. 
At present, indirect evidence suggests that nonspecific suppressor cells may play a 
role in the beneficial effect of blood transfusion on graft survival (Lenhard et al., 
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1982; Marque! et al., 1982; Opelz and Persijn, 1981). Some authors have presented 
evidence that Cy A selectively spares the expression of T suppressor cells (Leapman 
et al., 1980; Hess et al., 1981) and also does not affect their generation (Gunn eta!., 
1981). Considering these data, it is unlikely that the absence of the transfusion effect 
can be explained by the interference of CyA with suppressor cell action. On the 
other hand, preliminary evidence has been obtained by Marque! et al. (manuscript 
in preparation) that the action of suppressor cells was effectively abrogated by Cy A 
in an adoptive cell transfer assay. This finding would readily explain the phenome-
non observed in our study. Other T-cell-subset functions that are of crucial impor-
tance for the expression of a transfusion effect are possibly affected by CyA. It 
should be realized that attemps to elucidate the findings presented are speculative 
because the exact working mechanisms of both pretransplant blood transfusions 
and CyA are still poorly understood. 
In the present study, a dose-response relationship for Cy A and kidney graft survi-
val was found, thus confirming reports from other workers (Homan eta!., 1980a; 
Caine et al., 1979b). Yet, a dose of 10 mg CyA was suboptimal, 10 of 13 recipients 
surviving the administration course. At dosages of 5 to 10 mg, continuous admi-
nistration of the drug seems necessary to maintain graft survival; after termination 
of CyA treatment, rejection inevitably occurred. Most dogs surviving for 28 days re-
ject their graft one to three weeks after stoppage of CyA treatment, which is in the 
range of survival of nontreated controls. It seems therefore as if CyA reversibly 
blocks the immune response towards the graft. The findings in dogs are in agree-
ment with those in rhesus monkeys (Borleffs et al., 1981), but are at variance with 
those in rodents. In rats and rabbits, a short course of CyA can induce permanent 
organ graft survival (Homan et al., 1980e; Niessen et al., 1982a; Dunn et all980a). 
Serum creatinine levels on day seven were significantly elevated with 5 mg but not 
with 10 mg CyA, as compared with conventional immunosuppression; this finding 
indicates that the observed disturbance in kidney function is not primarily caused by 
a nephrotoxic effect of CyA. Further evidence supporting this speculation was ob-
tained in subsequent studies (see section 5.3). However, it is evident from clinical 
and experimental studies that CyA can definitely exert a nephrotoxic effect which is 
reversible after discontinuation or reduction of the dosage (Gluckman et al., 1981; 
Klintmalm et al., 1981; Hamilton et al., 1981; Thomson et al., 1981). A hepatotoxic 
effect of Cy A which occurs at higher doses of Cy A and is likewise reversible has also 
been reported from clinical studies (Caine et al., 1979a; Powles et al., 1980; Starzl et 
al., 1981 a). In the present study, the 5 mg dose caused a significantly lower increase 
in alkaline phosphatase level than did Aza/Pred, whereas the 10 mg dose did not. 
This phenomenon was observed on days five and ten. The difference between the 5 
mg/kg/ day dose and the I 0 mg/kg/ day dose was not significant on any day. As was 
known from earlier studies in nonimmunosuppressed dogs (Westbroek eta!., unpu-
blished results), transient increases in serum liver enzyme levels are evident until ten 
days following transplantation. Those values could not be compared with the pre-
sent findings because determinations and baseline levels were different. Although 
the mentioned posttransplant increase makes the interpretation of the current data 
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somewhat difficult, it is likely that the higher - though not significant - alkaline 
phosphatase levels at 10 mg Cy A are caused by a superimposed hepatotoxic effect of 
the drug during a period when the liver is more vulnerable. As a matter of fact, it ap-
pears from these data that conventional immunosuppression, i.e., azathioprine, 
may be significantly more hepatotoxic than 5 mg/kg/day CyA during this early 
posttransplant period. ln contradiction is the report by Starzl et al. (1981a) that one 
patient had to be switched from CyA to azathioprine because of the hepatotoxicity 
of CyA more than a year postoperatively. It seems that hepatotoxicity is no longer a 
serious problem now that more information is available on the optimal dosages and 
serum levels of CyA can be determined (Caine et al., 198lb). 
No indication of a myelotoxic effect could be shown in the present study. This con-
trasts sharply with the decrease in leukocyte counts seen on Aza/Pred in about 70% 
of the recipients surviving for longer than one month. 
In summary, the beneficial blood transfusion effect was not demonstrable when 
CyA was used as the only postoperative immunosuppressant. A dose-effect relati-
onship was found. No nephrotoxic effect or lower leukocyte counts were found at 
the dosages of the drug used. Slight hepatotoxicity seemed to occur only during the 
early posttransplant phase. Kidney transplant recipients treated with CyA only may 
receive no additional benefit from deliberate pretransplant blood transfusions. 
5.2. THE EFFECT OF CYCLOSPORJN A IN COMBINATION WITH 
AZATHIOPRINE AND PREDNISOLONE IN TRANSFUSED AND 
NONTRANSFUSED RECIPIENTS 
Introduction 
As has been shown in the preceding section a blood transfusion effect cannot be de-
monstrated when Cy A is used as the only immunosuppressant. Administration of 
Aza/Pred seems to be necessary for the expression of the transfusion effect in dogs. 
It would be worthwhile to combine a suboptimal dosage of CyA (10 mg/kg/day) 
with the conventional immunosuppressants azathioprine and prednisolone to study 
whether a blood transfusion effect was demonstrable and whether immunosuppres-
sion would be more optimal. 
'fhe combination of CyA with Aza/Pred has been considered harmful or at least a 
therapy that should be avoided to decrease the incidence of serious, often lethal, in-
fections in clinical practice (Caine et al., 1979a; Caine, 1980a; Sweny et al., 1981). 
Also in a rabbit kidney graft model, the combination of CyA with corticosteroids 
proved to be deleterious (Dunn et al., 1980b). Early death and sepsis occurred signi-
ficantly more often in recipients treated with CyA and steroids than in rabbits recei-
ving CyA only. In contrast, a clinical study by Starzl et al. (1980) stresses that the 
addition of corticosteroids might increase the value of CyA. The side effects repor-
ted by these authors were not serious. Studying several drug regimens using CyA in 
dogs Homan et al. (198lc) found that the combination of CyA with low-dose pred-
nisolone did not result in increased morbidity. 
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The present study was undertaken to investigate whether: 
1) a blood transfusion effect would be demonstrable when Aza/Pred were used for 
background immunosuppression and CyA was administered for a limited period 
of time at a suboptimal dosage; 
2) the combined immunosuppressive therapy would result in better graft survival 
than either Cy A alone for 28 days or the combination of Aza/Pred alone; 
3) a combined drug regimen would result in more side effects than either of the two 
constituents separately. 
At operation, two beagle dogs which were mostly DLA-identicallittermates of the 
same sex received a kidney from the same mongrel donor. Cy A was administered at 
a dose of 10 mg/kg/day for 28 days. Aza/Pred were administered at standard dosa-
ges, viz., 2 mg/kg/day and 1 mg/kg/day for 65 days; thereafter, the drugs were ta-
pered off for another 50 days. 
Results 
The survival times of the experimental groups are graphically shown in Fig. 5.2.1. 
For comparison, the survival times of dogs treated with Aza/Pred only are also de-
picted. The individual survival times and the crossmatch data are given in Table 
5.2.A.; the survival data of recipients treated with CyA 10 mg/kg/day only are also 
included (see section 5.1.). 
In the group treated with combined immunosuppression, a dichotomy of the survi-
val times of transfused and nontransfused recipients can be seen; 500Jo (4) transfused 
recipients survived for sixty days versus 130Jo (1) of non transfused recipients. For 
the purpose of comparison with the Aza/Pred group, a cut-off point of sixty days 
was chosen: in reality, the transfused dogs are still alive ( > 1 year) and the remaining 
nontransfused one survived for 139 days. The tendency of prolonged survival of 
transfused recipients over nontransfused recipients is again demonstrable when the 
DLA-identicallittermates are compared pairwise (Fig. 5.2.ll). The difference bet-
ween transfused and non transfused recipients is however not significant. A similar 
dichotomy effect as was observed on combined immunosuppression can be seen to 
occur earlier and more pronounced in the group treated with Aza/Pred; 600Jo of 
transfused recipients survived for sixty days versus II OJo of nontransfused recipients 
(p < 0.01). 
Nontransfused dogs treated with combined immunosuppression and subsequently 
with conventional drugs did not survive longer than nontransfused recipients treated 
with CyA only. These nontransfused dogs rejected their transplants after stoppage 
of CyA, irrespective of concomitant Aza/Pred administration, at a time interval 
which is approximately normal for untreated controls. The same observation ap-
plies to the transfused dogs which rejected their grafts. 
Two transfused dogs which were treated with combined immunosuppression develo-
ped infections. One had to be killed because of a serious eye infection, with a stable 
kidney function, at 47 days. Another long surviving dog was striken with pneumo-
nia four days after termination of Cy A treatment; this could be succesfully treated 
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Fig. 5.2.1. Kidney graft survival in transfused and nontransfused dogs treated with the combination of 
azathioprine, prednisolone and cyclosporin A at 10 mg/kg/day (A/P /C) or with azathioprine 
and prednisolone only (AlP). Cyclosporin A was administered for 28 days. 
Table 5.2.A. Survival times of transfused and nontransfused dogs treated with cyclosporin A only, with 
cyclosporin A in combination with azathioprine and prednisolone and with azathioprine 
and prednisolone only. 
Cyclosporin A 10 mg/kg CyclosporinA I 0 mg/kg Azathioprine 2 mg/kg 
Azathioprine 2 mg/kg Prednisolone 1 mg/kg 
Prednisolone l mg/kg 
No transfusion 11 33 34 42 26 30 33 37 11 15 16 19 
42 44 47 48 41 43 47 )60 20 29 30 48 
)60 
Transfusions 12+ 13+ 37 40 25 35 40+ 46 21 26 49 51 
44 )47' )60 )60 )60 )60 )60 )60 )60 
)60 )60 
+ positive crossmatch test (one- or two- stage microlymphocytotoxicity test) 
• killed because of eye infection, with stable kidney function (creatinine 127 J-lmole/1) 
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Fig. 5.2.11. Paired comparison of kidney graft survival in transfused and nontransfused DLA-identical 
littermates treated postoperatively with cyclosporin A, azathioprine and prednisolone. 
Cyclosporin A was administered for 28 days. *:Killed because of eye infection, with stable 
kidney function. 
with a five-day course of lincomycin at 300 mg/ day and kanamycin at 250 mg/ day. 
In both animals infections occurred during a period in which leukocyte counts drop-
ped below 3 x 109 /l. These decreases in the leukocyte counts on combined immuno-
suppression were seen somewhat less frequently than on Aza/Pred (55"7o versus 
67"7o) and were of equal duration (2-21 days; median 14 days). The serum creatinine 
level at day seven was significantly lower in dogs on combined immunosuppression 
as compared with those on Aza/Pred (p ( 0.05); kidney function on different im-
munosuppressive regimens will be more extensively evaluated and discussed in secti-
on 5.3. Except for diseased kidneys and the eye infection mentioned no abnormali-
ties were found at autopsy. Kidney specimens were not different from those seen on 
cenventional immunosuppression. 
Discussion 
In the present study, graft survival in transfused dogs which received CyA and 
Aza/Pred was prolonged(> 60 days) in 3 (4) of 8 recipients, as opposed to I of 8 
nontransfused recipients; the only nontransfused dog ultimately died at 139 days, 
whereas the long-term surviving transfused dogs are still alive(> I year). A dissocia-
tion of survival times between transfused and non transfused recipients can be seen 
only after stoppage of CyA (Fig. 5.2.I). When CyA was used as the only postopera-
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live immunosuppressant for a limited period of time, all grafts were rejected (secti-
on 5.1.) in both transfused and nontransfused recipients. When Aza/Pred were used 
for postoperative immunosuppression, a significant transfusion effect could be ob-
served, 6 of 10 transfused dogs showing prolonged survival versus I of 9 nontrans-
fused dogs (Obertop et al., 1978b). Thus, the results from the present study show an 
improvement in survival that is intermediate between those of the two regimens se-
parately. Although the difference in survival between transfused and nontransfused 
recipients is not significant, it seems logical to attribute the greater prolongation in 
transfused dogs to the pretransplant transfusions in view of the results from the pre-
ceding experiments. 
Considering the results of these experiments in relation to each other, it is likely that 
the presence or absence of the transfusion effect can be explained by a differential 
action of Aza/Pred or CyA on the immunological mechanism that is responsible for 
the transfusion effect. The different mechanism of CyA may have resulted in a par-
tial interference with the action of Aza/Pred, which probably gave rise to the dimi-
nished expression of the transfusion effect in the present study. It remains to be de-
termined whether a better transfusion effect can be obtained when recipients are ini-
tially treated with CyA alone and subsequently converted to Aza/Pred or vice versa. 
When CyA was discontinued in the present study, all non transfused dogs rejected 
their transplants after a period of time that was normal for nontreated controls. The 
same phenomenon was observed after discontinuation of CyA as the only immuno-
suppressant (section 5.1.). Obviously, the addition and continuation of Aza/Pred 
was not additive to the immunosuppressive regimen used in terms of graft survival. 
It is known that the combination of Aza/Pred in itself has a moderate immunosup-
pressive effect in nontranfused dogs (Obertop et al., 1978b, Fabre et al., 1978; Ho-
man et al., 1981c). The lack of additional effect in this study might be related to the 
fact that a dose of 10 mg CyA is suboptimally effective. This could be deduced from 
the finding that converting from an optimal dose of CyA to Aza/Pred resulted in 
prolonged survival which could not be explained by the immunosuppressive activity 
of Aza/Pred alone (section 5.3.; Homan et al., 1981c). 
Several authors have warned of the danger of combining CyA with conventional 
immunosuppressants, especially with regard to the occurrence of serious infections 
(Caine et al., 1979a; Sweny et al., 1981). In the current study, two dogs developed a 
serious infection; normally, the occurrence of an infection is rare in our dogs on 
Aza/Pred. Both infections occurred while the leukocyte counts were below 3.109 /I. 
At that time, the animals were already off CyA and azathioprine administration had 
been stopped according to protocol (see Materials and Methods). The frequency and 
duration of the depressed leukocyte counts give no indication for a more myelotoxic 
effect of the combined regimen (CyA/ Aza/Pred) than of Aza/Pred. It is not rea-
listic to conclude from these two observations that combined immunosuppression 
predisposes to severe infections, but they serve as a warning to be alert. 
Though not measurable in graft survival, the combined regimen seems to exert a 
more profound immunosuppression in terms of kidney function. The combination 
of CyA and Aza/Pred results in a significantly better (p < 0.05) kidney function 
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than either of the two regimens on the seventh posttransplant day. According to the 
other results obtained, this better kidney function is a reflection of better immuno-
suppression (see section 5.3.). 
Briefly summarizing, for the expression of the beneficial blood transfusion effect, 
Aza/Pred seems to be necessary, either as initial therapy or after discontinuation of 
Cy A. Addition of Aza/Pred to a suboptimal dose of 10 mg Cy A does not lead to an 
additional prolongation of graft survival. No dramatic increase in infection fre-
quency was observed. 
5.3. DOSE-RESPONSE STUDIES OF CYCLOSPORIN A AND THE EFFECT 
OF CONVERTING TO CONVENTIONAL IMMUNOSUPPRESSANTS IN 
NONTRANSFUSED DOGS. 
Introduction 
Especially in the early days of the clinical use of cyclosporin A (CyA) precise know-
ledge concerning an optimal dose-effect relationship was lacking (Caine et al., 
1979a, 1979b). This knowledge is particularly important with respect to its dose-
dependent side-effects such as the described nephrotoxicity and hepatotoxicity (Cai-
ne et al., 1978b; Powles et al., 1980). Several transplantation studies in experimental 
animals have yielded conflicting results for different species. In rodents, a short 
course of CyA proved to be sufficient to result in indefinite organ graft survival 
(Green et al., 1978; Marque! et al., 1981), although skin grafts were rejected after 
termination of CyA administration (Borel et al., 1976). In outbred animals, rejecti-
on of both organ and skin grafts inevitably followed stoppage of CyA administrati-
on (Homan et al., 1980a, Niessen et al., 1981; Deeg et al., 1980). Also the minimal 
dose that is required to prevent rejection proved to be different in various studies; 
among others, this is possibly dependent upon the method of administration (Kosta-
kis et al., 1977a, Niessen et al., 1982a; Homan et al., 1980e). 
It appears from clinical studies that changing to and from CyA endangers seldom 
the function of the kidney (Caine et al., 1981b). Homan et al., (1981c) showed that a 
change to conventional immunosuppressants (Aza/Pred) after a long-term course 
of CyA was followed by prolonged renal allograft survival which could not be ex-
plained by the immunosuppressive effect of Aza/Pred only. This observation sug-
gests that prior CyA administration can influence graft survival after changing to 
conventional immunosuppressants. 
In our model, we attempted to define a dose-response relationship for CyA, see-
king for the minimal dose that would prevent rejection of kidney allografts during 
the period of Cy A therapy. Also the effect of converting to Aza/Pred after a 28-day 
course of CyA administration was studied to see whether effective suppression of 
graft rejection could be safely continued by changing to conventional immunosup-
pressants at that time. In evaluating the dose-effect relationship for CyA in canine 
renal allografting, this study is an extension of the nontransfused group described in 
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section 5.1. Apart from the beagles in the previous group, the other recipients pre-
sented here were all mongrel dogs that received a kidney from an incompatible beag-
le donor. CyA was administered at different doses for 28 days. Seven of ten dogs 
that received Cy A at 15 mg/kg/ day and all of those that received the drug at 25 
mg/kg/ day were converted to Aza/Pred after discontinuation of Cy A treatment. 
Administered from 65 days after transplantation, Aza/Pred were tapered off for 
another 50 days. 
Results 
The survival times of the dogs, including the recipients that were converted to 
Aza/Pred, are plotted in Fig. 5.3.!.: for completion, the pertinent data from section 
5.1. were added. The individual survival times and other information pertaining to 
the mongrel recipients are given in Table 5.3.A. The survival times of control dogs 
treated with Aza/Pred postoperatively are given in Chapter 3. Administration of 
Cy A at a dose of 2 mg/kg/ day did not prolong renal allograft survival. Cy A 5 
mg/kg/day led to significant prolongation of renal allograft survival (p < 0.005) and 
doubling the dose of the drug to 10 mg/kg/day further improved allograft survival 
significantly over that of the 5 mg/kg/day dose (p < 0.025). Seven of 8 dogs treated 
with CyA at 10 mg/kg/day survived for the duration of therapy; 5 of these 7 dogs 
rejected their kidneys at an untreated control survival time if calculated from the 
day of stoppage of CyA. Unexpectedly short were the survival times of the dogs on 
15 mg/kg/day; only 3 of 10 animals survived CyA treatment and were subsequently 
treated with Aza/Pred. One of these dogs survived for 170 days and the other two 
rejected their kidneys at untreated control survival times if calculated from the day 
of converting. The 7 dogs that rejected their kidneys under CyA therapy (15 
mg/kg/day) did so at the same survival time as did untreated controls. All four dogs 
treated with CyA at 25 mg/kg survived for 28 days. One of these animals is still alive 
for more than one year; a second survived for 123 days and the other two rejected 
their kidneys at a control time for dogs on Aza/Pred if the day of converting wasta-
ken as the day of transplantation. 
The serum creatinine levels for all experimental groups mentioned in this chapter are 
graphically shown in Fig. 5.3.1!. Only dogs surviving for longer than four weeks we-
re considered and values were included until rejection was imminent. A tendency of 
improving kidney function with increasingly potent immunosuppression seems evi-
dent. Yet, only some differences are significant at day seven (Student's !-test). Se-
rum creatinine levels are significantly higher during treatment with CyA at 5 
mg/kg/day when compared with Aza/Pred (p ( 0.05) or Aza/Pred/CyA 
(p ( 0.05). Levels were also significantly higher on CyA 10 mg/kg/day as compared 
with Aza/Pred/CyA (( 0.05). Further, creatinine levels are significantly higher on 
Aza/Pred than on Aza/Pred/CyA (p ( 0.05). Autopsies and histology resulted in 
no peculiar findings. 
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Fig. 5.3.1. Kidney graft survival in dogs treated postoperatively with different doses of cyclosporin A. 
Cyclosporin A (CyA) was stopped at 28 days after transplantation. Seven dogs on CyA at 15 
mg/kg/day and all of those on CyA at 25 mg/kg/day were converted to azathioprine and 
prednisolone after cessation of Cy A treatment. 
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Table 5.3.A. Survival times (days) of dogs depicted in Fig. 5.3.1. 
CyA 0 mg/kg/day 7 (F) 7 (M) 8 (M) S (F) 
8 (F) 9 (F) 9 (M) 10 
12 (M) 12 (M) 12 (M) 13 (F) 
14 (M) 19 
CyA 2 mg/kg/day 8 (F) 9 12(M) 12 
CyA 5 mg/kg/day 10 (F) 12 (M) 16(M) IS 
19 20 (M) 20 21 
26 (F) 35 70 
CyA 10 mg/kg/day II (F) 33 34 (M) 42 (M) 
42 44 (M) 47 48 
CyA 15 mg/kg/day 7 (F) S (F) 8 (F) 9 (F) 
14 (F) 17 (F) IS (F) 39 (F) 
46 (M) 170 (M) 
CyA 25 mg/kg/day 49 (M) 62 (M) 123 (M) ) 200 (M) 
CyA: cyclosporin A. For mongrel recipients a sex indication is added. M: male, F: female. 
Discussion 
It is evident from the data presented that CyA is a very potent immunosuppressant. 
A dose-effect relationship for CyA in canine kidney transplantation had already 
been shown (Homan et al., !980a) and could be contirmed in our dog model, with 
the exception of the 15 mg dose (see also section 5.1.). 
The survival data in the 15 mg group were rather unexpected because 5 of I 0 reci-
pients rejected their grafts at a time appropriate for nontreated controls, while only 
1 of 8 recipients did so on 10 mg CyA. Therefore, we attempted to analyse the diffe-
rent recipient-related factors that might influence graft survival. The major factors 
influencing graft survival have been found to be recipient-related (Jonassen and 
Moses, 1981). All recipients in the 15 mg and 25 mg groups were mongrels. As men-
iioned under "Materials and Methods" these mongrels were obtained indirectly 
from local dog handlers and hardly anything was known about their history. It was 
known that some females had been pregnant but the ages could only be estimated. 
Considering the 15 mg group, it is striking that only 2 of 10 recipients were male; 
they survived for 46 to 170 days. Three of 8 bitches were known to have borne pup-
pies; these survived for 7, 8 and 8 days, respectively. Two of the remaining 5 bitches 
appeared morphologically old and were found to have a multiparous uterus at ope-
ration; they survived for 7 and 14 days. The other three bitches seemed young and 
proved to have a virgin uterus at operation; they died at 17, 18 and 39 days. From 
the above-mentioned data, it can be speculated that old age and pregnancies pre-
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Fig. 5 .3.Il. Posttransplant serum creatinine levels, before beginning of rejection, on different immuno-
suppressive regimens. Values given are mean values expressed as percentages of preoperati-
ve cont:ollevels. The number of dogs are given in parentheses. C5, CJO, Ct5• C25: cy-
closponn A at 5, 10, 15 or 25 mg/kg/day. AlP: azathioprine and prednisolone (conventio-
nal immunosuppression); A/P/Cto: azathioprine and prednisolone in combination with cy-
closporin A at 10 mg/kg/day (combined immunosuppression); S: significant at a level of 
p < 0.05 (Student's t-test). 
dispose to shorter graft survival. Dogs which have been pregnant several times are 
more likely to be old. It has been found in clinical studies that cytotoxic antibodies 
are more frequently present in parous females (Opelz et al., 198lc). 
Still, some authors report a beneficial effect of previous pregnancies comparable 
with that of blood transfusions (Editorial, Lancet 1978; Hourmant et al., 1979; Fau-
chet et al., 1979), a finding that could not be confirmed in large multicentre studies 
(Opelz and Terasaki, 1978, 1980b; Spees et al., 1980; Jonasson and Moses, 1981). 
The latter studies do indicate a relation between old age and shorter graft survival. It 
is possible than some old breeding bitches were included in this 15 mg group and 
that graft survival was consequently influenced by advanced age. Although not very 
likely in view of the concomitant prolonged survivals, something may have been 
wrong with the Cy A solution. The present system for obtaining mongrel dogs makes 
a reliable evaluation of factors that may influence graft survival impossible. In fact, 
no difference in survival was seen between beagle recipients and mongrel recipients 
receiving a mismatched kidney. 
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A dosage of 25 mg CyA seems to be optimal, as all dogs fully survived the admi-
nistration period. No side effects were seen on either this fairly high dosage or the 
lower ones used in this study. 
Dogs that survived 28 days in the 15 mg or 25 mg group and were subsequently 
converted to Aza/Pred showed a dual pattern of survival. Either they rejected their 
graft at a time which would coincide with Aza/Pred treated recipients if calculated 
from the day of conversion or they showed markedly prolonged survival times 
(> 100 days). This marked prolongation cannot be explained by the effect of 
Aza/Pred alone but probably reflects a special state of diminished immune respon-
siveness induced by the previous CyA administration. A similar phenomenon has 
been observed by Homan et al., (1981c) when CyA at a dose of 20 mg/kg/day was 
administered for 100 days and then substituted or not by Aza/Pred. Dogs that were 
converted to Aza/Pred also showed a markedly prolonged survival, whereas those 
that were not converted rejected their grafts at control survival times. These authors 
did not investigate whether short-term administration of 20 mg CyA would give the 
same results. In view of our data on doses of 15 mg and 25 mg, it could be expected 
that prolonged graft survival could be noted after converting. 
When we consider the creatinine levels of the recipients that survived for more 
than 28 days on CyA or on combined immunosuppression (Aza/Pred/CyA), a ten-
dency for better kidney function with improving immunosuppression is suggested 
(Fig. 5.3 .II). Some differences were significant (p ( 0.05) on day seven: creatinine 
levels on 5 mg CyA were higher than on Aza/Pred or on Aza/Pred/CyA; levels on 
10 mg CyA were also higher than on Aza/Pred/CyA. These data merely underline 
the observed tendency that better immunosuppression coincides with lower creatini-
ne levels, which is identical to better kidney function. In this respect, our data would 
support the view of Starzl et al. (1980) that deterioration of kidney function often 
merely reflects the presence of chronic rejection rather than the nephrotoxic effect 
of the instituted therapy. 
No nephrotoxic effects by CyA were observed in the present study, since increasing 
doses of the drug resulted not in decreases in kidney function but rather in better 
kidney function. This is in accord with experimental data from studies in dogs and 
monkeys, also showing no nephrotoxic effect of doses of up to 20 mg/kg/day or 25 
mg/kg/day CyA, respectively (Homan et al., 1980a; Borleffs et al., 1981). The data 
in outbred experimental animals are in contrast with those from clinical studies: a 
nephrotoxic effect has already been observed by most clinicians at therapeutic doses 
(Caine et al., 1979a; Powles et al., 1980; Starzl et al., 198la; Gluckman et al., 1981). 
To summarize, a dose-response relationship could be confirmed for CyA in cani-
ne kidney transplantation up to a dose of 25 mg/kg/day. Several short-term survi-
vals on 15 mg/kg/day could not be readily explained. 
Short-term (28 days) treatment with 25 mg/kg/day CyA proved to have a beneficial 
influence on graft survival when a subsequent change to Aza/Pred was made. CyA 
was not nephrotoxic in this dog model. 
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CHAPTER6 
GENERAL DISCUSSION AND CONCLUSIONS 
An attempt has been made in this study to provide answers to the several unsolved 
questions concerning the effects of blood transfusion and immunosuppression on 
graft survival. 
6.1. BLOOD TRANSFUSION 
Although a beneficial blood transfusion effect has been generally recognized (Opelz 
and Terasaki, 1980a), several questions remain to be answered before a deliberate 
clinical blood transfusion policy can be adopted. 
Patients in whom the blood transfusion effect has been studied were mostly treated 
with the conventional immunosuppressants azathioprine and prednisolone. Conse-
quently, nothing was known with respect to the immune suppressive, or more preci-
sely, the survival promoting effect of pretransplant blood transfusion per se. Some 
studies had been performed on the effect of blood transfusions without the use of 
immunosuppressants in preclinical dog models. No significant beneficial effect on 
graft survival could be demonstrated using either donor-specific (Currier and Pier-
ce, 1974; Sutherland et al., 1979) or pooled third-party blood (Bullet al., 1978). On-
ly in the previously mentioned study by Halasz et al. (1964) was prolonged graft sur-
vival obtained following subcutaneous administration of donor blood. The data 
from the latter study must be considered an artifact, as the results were not reprodu-
cible in two independent studies following the same protocol (Obertop et al., 1975; 
Sutherland et al., 1979). 
The experiment on the transfusion effect per se reported here clearly demonstrated 
that no beneficial effect on graft survival was obtained without conventional immu-
nosuppression. Yet, this finding cannot be readily extrapolated to the clinical situa-
tion, because patients on dialysis are uremic. It is known that uremia causes a de-
pressed immune reactivity (Fehrman et al., 1981) which might have some bearing on 
the expression of the transfusion effect. It seems not justified, however, to treat pa-
tients with pretransplant transfusions only on the basis of our findings. 
Although pretransplant blood transfusions alone may have no manifest effect on 
graft survival without postoperative immunosuppression, another indication of the 
influence of blood transfusion on the immune response in man was observed in im-
munosuppressed recipients receiving a kidney from donors who were transfused 
shortly before death. It was found in two retrospective studies reporting on three 
transplantation centers that grafts from transfused cadaveric donors showed signifi-
cantly prolonged survival times, especially when the recipients had also been trans-
fused before transplantation (Jeekel et al., 1981; Frisk et al., 1981). The retrospecti-
ve finding that transfusions to the donor can influence graft survival is supported by 
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the data from experiments in rats (Jeekel et al., 1982). However, in rats, the effect 
of transfusions to the kidney donor is mainly detrimental for the graft. It should be 
realized that the effect of donor transfusion, if it should be proved to be real, may 
have obscured transfusion data from previous studies. 
If a deliberate blood transfusion policy should be adopted, a minimum number of 
transfusions would be preferable from both a practical point of view and in view of 
the fear of sensitization. If a similar beneficial effect could be obtained by peropera-
tive transfusions only, that would be the ideal way of treatment, since sensitization 
would be prevented and the transfusion would constitute no extra burden to the pa-
tient. An optimal or near-optimal beneficial effect (80"7o one-year graft survival) of 
I pretransplant blood transfusion was reported from only two centres (Persijn et al., 
1979; Williams et al., 1979). However, a single transfusion in the dog model proved 
to be only marginally effective, with concomitant pretransplant immunosuppression 
(van der Linden et al., 1982). ln our dog model using Aza/Pred for immunosup-
pression, no significant beneficial effect of a single pretransplant blood transfusion 
could be shown. This could be explained by a threshold effect in the dog; possibly, a 
certain number of transfusions is necessary to exert an effect, as three transfusions 
cause a significant prolongation of graft survival in the same model (Obertop et al., 
1978b). ln the dog, there seems to be a dose-response relationship, just as was 
shown in the monkey (vanEs et al., 1977, 1978) and in man (Opelz and Terasaki, 
1980a). 
There is even more controversy over the effect of peroperative transfusions in 
man. After the initial communication of Stiller et al. (1978) reporting a positive ef-
fect of transfusion during operation, the majority of the following reports did not 
support their finding (Brynger et al., 1978; Salaman, 1978; Persijn and van Rood, 
1978); also in multicentre data no improvement effect could be shown (Opelz and 
Terasaki, 1980b, 1981). Although van der Linden et al. (1982) could demonstrate a 
positive effect of peroperative transfusions in the dog, we could not confirm this in 
a small series of recipients. A conclusive answer to the question concerning the ef-
fectiveness of peroperative transfusion cannot be given. 
In an attempt to avoid sensitization as much as possible, studies were designed to 
obtain a beneficial transfusion effect while avoiding concomitant sensitization by 
means of matched blood transfusions. The results of two clinical pilot studies were 
controversial both with respect to the degree of sensitization and to the effect on 
graft survival (Nube et al., 1981; Albert et al., 1981). We tried to evaluate both 
aspects in our mongrel to beagle donor recipient combination. Because tissue typing 
in our beagles has been well established, as opposed to mongrels, beagle blood 
transfusions of different match grades were administered to beagle recipients. It was 
found that beagle blood had no beneficial effect on subsequent graft survival, ir-
respective of the number of different MHC antigens administered. This means that 
beagle blood lacks the factor(s) contained in mongrel blood which are necessary to 
induce the transfusion effect. lt may be that beagle blood contains fewer non-MHC 
antigenic differences that are probably important. This might be the result of the li-
mited polymorphism of minor histocompatibility systems as a consequence of selec-
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ted breeding in the beagle. In any event, this model using beagle blood in beagle reci-
pients is not suitable for studying the effect of matched transfusions. 
The relatively limited typing possibilities in mongrels preclude further study in the 
same donor-recipient combinations. On the other hand, it has become apparent 
from this study that MHC differences per se are not sufficient for the induction of a 
transfusion effect. It was also demonstrated that beagle blood can cause sensitizati-
on in beagles as well as can mongrel blood, but matched blood seems to lead to less 
sensitization than mismatched blood. 
From clinical studies, it became evident that the type of blood product administe-
red is important with regard to the transfusion effect. Frozen red blood cells appear 
less effective in multicentre studies than whole blood, packed cells or washed eryth-
rocytes (Spees et al., 1980; Opelz and Terasaki, 1980a), although this was not uni-
versally confirmed (Fuller et al., 1977). This Jesser or no effectiveness of frozen 
blood is probably attributable to the very low content of leukocytes. The absence of 
a transfusion effect after leukocyte-free blood transfusions supports this explanati-
on (Persijn et al., 1979). However, in monkeys (vanEs et al., 1978) and dogs (Ober-
top et al., 1979), both erythrocytes and leukocytes gave prolonged kidney graft sur-
vival. Little information existed about the effect of plasma and platelets on graft 
survival. In dogs, Harder et al. (1979) found an equivalent prolongation of graft 
survival following pretransplant administration of donor blood, donor plasma or 
third party blood in combination with preoperative immunosuppression but without 
postoperative immunosuppression. In our study, we found no effect of pre-
transplant plasma transfusions with postoperative Aza/Pred on canine kidney graft 
survival. So, pretransplant immunosuppression might be critical for the expression 
of a transfusion effect in the dog model following pretransplant administration of 
plasma or a single blood transfusion (van der Linden et al., 1982). Another outstan-
ding finding in the study of Harder et al. was the equal effect of donor blood and 
third party blood. 
Others have found that donor specific transfusion in dogs carries a high risk of do-
nor specific sensitization with an inherent poorer prognosis for the transplant (Cur-
rier and Pierce, 1974; Obertop et al., 1975; Sutherland et al., 1979). However, in 
these experiments no postoperative immunosuppression was given, which makes the 
graft survival data difficult to interpret. A high sensitization rate following donor 
specific transfusion was also confirmed for the human situation in one-haplotype 
related recipients. However, the nonsensitized patients did extremely well (Salvatier-
ra et al., 1981), suggesting that in addition to the nonspecific effect a donor specific 
enhancement effect may also play a role in the transfusion induced improvement in 
graft survival. Undoubtedly, the fact that donor and recipient were one-haplotype 
related makes a major contribution to the favourable results in this series, which can 
be derived from the low graft survival following donor specific transfusions from 
nonrelated individuals (Ruzany, personal communication). 
The possible mechanisms that underly the blood transfusion effect were discussed 
in the Introduction: there is ample evidence for a role of suppressor cells. In our rat 
model, direct evidence was found that suppressor T cells present after donor specific 
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transfusion could induce prolongation of heart allograft survival after adoptive 
transfer to syngeneic recipients (Marque! et al., 1982). In the same communication, 
it was shown that donor specific transfusion produces both a specific and a nonspe-
cific immunosuppression, which are both transferable by cells. However, in the rat 
model, the nonspecific immunosuppression induced by donor specific transfusions 
proved not to be sufficient to give rise to prolonged survival of third party heart al-
lografts. 
It cannot be denied that these findings bear some resemblance to the human situati-
on. Also in humans indirect evidence has been presented for the role of cell media-
ted immune mechanisms, especially suppressor T cells, in the transfusion effect 
(Lenhard et al., 1982). 
Summarizing, it can be said that present experimental and clinical evidence points to 
an important role of specific and nonspecific suppressor cells in the beneficial blood 
transfusion effect. 
6.2. IMMUNOSUPPRESSION 
In man, transplantation became feasible only after the introduction of the immuno-
suppressants azathioprine and prednisolone. 
Since their introduction, these immunosuppressants have remained the mainstay of 
immunosuppressive therapy in transplant patients. The effect of pretransplant 
blood transfusions on graft survival has consequently been studied in recipients who 
were almost universally treated with Aza/Pred. It is possible therefore that the com-
bination of Aza/Pred is a prerequisite for the manifestation of the transfusion ef-
fect. In dogs, immunosuppression with Aza/Pred had a significant but not dramatic 
effect on graft survival (p ( 0.01) (See sections 3.1 and 3.2). This conventional im-
munosuppressive regimen alone seldom gave rise to prolonged survival(> 60 days). 
When pretransplant blood transfusions were given, a pronounced improvement 
(p ( 0.01) in graft survival was seen when Aza/Pred were used postoperatively 
(Obertop et al., 1978b). These drugs rarely caused serious side effects in our dogs. 
Although a leukopenia was seen in 700Jo of recipients that survived for longer than 
one month, infections were seldom observed. No clinical signs of altered liver func-
tion were seen, despite the elevated serum alkaline phosphatase levels on Aza/Pred. 
In rats, Aza/Pred had a marginal effect on heart allograft survival (van Bekkum et 
a!., 1969). This might be attributable to the fact that in rodents azathioprine is ra-
pidly metabolized via an alternative pathway, thus diminishing its immunosuppres-
sive effect (Elion, 1977); on the other hand, corticosteroids are more "lympholytic" 
in rats than in monkeys or man, which are relatively corticosteroid resistant. 
The new immunosuppressant CyA has proved to be very potent in several experi-
mental transplantation models (Homan eta!., 1980a, 1980e; Borel and Meszaros, 
1980; Dunn et al., 1980a; Pennock et al., 1981). The drug exhibited remarkably few 
side effects in experimental animals, as opposed to man (Caine, 1980). Our experi-
ments in rats indicated that Cy A can overcome sensitization by donor -specific blood 
transfusion in the WAG/Ro to BN/Ro rat model. This is in contradiction with the 
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opinion generally held that Cy A does not act on the secondary immune response 
and consequently would not be of value for the treatment of sensitized patients 
(Morris, 198lb). In the reverse BN/Ro to WAG/Ro model, which exhibits a benefi-
cial blood transfusion effect after donor-specific transfusion, CyA did not interfere 
with the permanent survival effectuated by transfusion. To explain this permanent 
survival after CyA treatment, two hypotheses that suppose different actions of CyA 
can be advanced. If it is assumed that suppressor T cells are responsible for the 
transfusion effect, the present findings of permanent graft survival in CyA treated 
transfused recipients might be in accord with the claimed suppressor cell sparing ac-
tion of CyA (Leapman et al., 1980; Hess et al., 1981). The second hypothesis is that 
CyA prolongs graft survival merely by its immunosuppressive action. An indication 
for this may be found in the low dose of 5 mg/kg CyA which is sufficient to obtain 
permanent graft survival in the weak BN/Ro to WAG/Ro model. Thus, it is not im-
possible that CyA interferes with the expression of the transfusion effect by inhibiti-
on of suppressor cells, because it suppresses allograft rejection at the same time. The 
evidence presented by Hutchinson et al., (198lb) that CyA allows the emergence of 
specific suppressor cells is not totally convincing. They claim the emergency of spe-
cific suppressor T cells. Adoptive spleen or thymus cell transfer was performed on 
days 7, II, 21, 50 and 100 after transplantation. CyA was administered for seven 
days posttransplant. Although the presence of suppressor cells on day II is in fa-
vour of their theory, the absence of a suppressor effect casts doubt on it. It would 
have been more convincing if CyA had been administered for a longer period of ti-
me and led to the same results. If Cy A were to allow free proliferation of suppressor 
T cells, these cells might have been present on day 7 as well. Their presence at four 
days after termination of CyA treatment might mean that these cells only appear af-
ter discontinuation of CyA administration. Their findings could equally mean that 
Cy A acts by vigorous nonspecific T -cell suppression, with the effect of Cy A prevail-
ling on more numerous cytotoxic T cells. It is known that rats with long-standing 
heart or kidney allografts, induced by any method, exhibit donor-specific immunity 
which can be transferred by adoptive cell transfer of spleen suppressor cells (Morris, 
198lb; Marque!, 1978). The demonstration of a CyA induced phase of nonspecific 
immunosuppression followed by a later specific phase (Nagao et al., 1982) is not in 
contradiction with the latter phenomenon. 
The concept of Cy A allowing the expression of suppressor T cells by suppression of 
cytotoxic T cells is attractive, but the experimental evidence is not conclusive, as al-
ready mentioned by Morris (1981b). 
Our experiments in dogs showed a clear dose-effect relationship for CyA in renal 
transplantation, thus confirming previous experiments in dogs (Homan et al., 
1980a). Only the survival rates on 15 mg/kg CyA were unexpectedly low; the possi-
ble factors underlying this finding have been extensively discussed in section 5.3. It 
was found that rejection always occurred after cessation of CyA therapy unless 
other immunosuppressive treatment was given. In most animals, rejection occurred 
at 8-25 days after cessation of CyA, in both transfused and nontransfused reci-
pients. The average amount of time elapsed after discontinuation of therapy is simi-
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Jar to the average survival time of nonimmunosuppressed recipients. From these da-
ta, it seems that CyA temporarily delays the onset of the immune response towards 
foreign antigens. This would also explain the reappearance of the blood transfusion 
effect on Aza/Pred following discontinuation of CyA therapy. 
In species other than rodents, rejection of organ allografts was almost always seen 
after discontinuation of CyA (Homan eta!., 1980a; Bor1effs eta!., 1981; Deeg et 
a!., 1980; Pennock eta!., 1981). A remarkable exception to this was observed in the 
pig (Caine eta!., 1978a). CyA proved to also be an extremely potent immunosup-
pressant in the dog model. On 10 mg, approximately 80"7o of the recipients survived 
the duration of CyA therapy (28 days). Graft survival was significantly prolonged as 
compared with standard doses of Aza/Pred. 
When a combined therapy using both CyA and Aza/Pred was given, the addition of 
Aza/Pred did not contribute effectively to the immunosuppressive potency of the 
instituted regimen in terms of graft survival. However, kidney function was better 
on combined immunosuppression than on either CyA (10 mg/kg) or Aza/Pred alo-
ne. 
A dose of 25 mg/kg CyA was optimal or above optimal; all recipients fully survived 
the administration time. The subsequent survival of two of four recipients after con-
version to Aza/Pred cannot be explained on the basis of the immunosuppressive ef-
fect of Aza/Pred only. The extraordinarily long survival times may also be attribu-
table to the lasting decreased immune responsiveness induced by a relatively high 
dose of CyA administered for a limited period of time. The same observation of a 
markedly prolonged survival on Aza/Pred was made by Homan et al. (1981c) after 
100 days of treatment at a lower dose of CyA (10 or 20 mg/kg). 
From the above-mentioned data, it can be deduced that conversion from Cy A to 
Aza/Pred does not seem to create serious hazards but may rather be advantageous. 
Probably, a switch from Aza/Pred to CyA would not do any harm either. The easy 
convertibility from and to either regimen seems to hold true for the clinical situation 
as well (Caine eta!., 1981b). Although not many, some side effects were noticed in 
our animals. In some rats a general wasting, which was reminiscent of a picture des-
cribed for Graft Versus Host Disease and which eventually led to death, was obser-
ved on doses of 15 mg/kg CyA given for seven days (unpublished observations). 
This situation persisted or developed after cessation of CyA therapy. No further un-
toward side effects were seen after the employed short course of CyA. In dogs, the 
elevated serum creatinine levels observed proved to be a reflection of suboptimal im-
munosuppression. With increasingly better immunosuppressive treatment in terms 
of graft survival, serum creatinine levels were lower. This finding supports the view 
of Starzl et a!., (1980) that elevated serum creatinine levels are not necessarily a sign 
of nephrotoxicity but can also be a reflection of persistent chronic rejection. 
A light subclinical form of hepatotoxicity as evidenced by elevated serum alkaline 
phosphatase levels was also observed in our dogs. No significantly greater number 
of severe infections was seen in our dogs on combined immunosuppression con-
sisting of CyA and Aza/Pred, as has been described for the clinical situation (Caine 
eta!., !980a). In particular, no lymphomas were seen at autopsy; this is not surpri-
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sing in consideration of the short administration time. It can be concluded that CyA 
has a very high therapeutic index, certainly in experimental animals. It is a very po-
tent immunosuppressant with only few side effects, especially when used at thera-
peutic dosages. Contrary to the prevailing opinion, it has been shown that CyA can 
also be used with success in sensitized rat recipients. It would be worthwhile to test 
the drug in more numerous outbred animal models using sensitized recipients. Con-
version to conventional immunosuppression and probably also vice versa does not 
seem to constitute a serious problem. 
6.3. THE RELATIONSHIP BETWEEN BLOOD TRANSFUSION AND IMMU-
NOSUPPRESSION 
?retransplant blood transfusions prolong kidney graft survival in man (Opelz and 
Terasaki, !980a). However, it should be realized that this has been proved only for 
patients who received azathioprine and prednisolone for postoperative immunosup-
pression. 
It was shown in our dog model that pretransplant blood transfusions exert a benefi-
cial effect on graft survival only in combination with postoperative conventional im-
munosuppression. Obviously, the effect of blood transfusions per se on the immune 
response is not sufficient to cause a significant prolongation of graft survival. 
When CyA was used as the only postoperative immunosuppressant for 28 days, 
no transfusion effect was observable. Even at a low dose of 5 mg/kg CyA, which is 
not sufficient to maintain graft survival during the period of administration, no dif-
ference in survival between transfused and nontransfused recipients could be 
shown. The latter observation precludes the overriding immunosuppressive effect of 
Cy A as the causative factor in explaining the absence of the transfusion effect. On 
conventional immunosuppression, a clear divergence of graft survival time between 
transfused and nontransfused dogs was noticeable at 28 days: 80 vs. 24 percent, 
respectively (Obertop et al., 1978b). When CyA and Aza/Pred were administered 
concomitantly, a divergence in graft survival between transfused and nontransfused 
recipients became apparent only after discontinuation of CyA. Although not sta-
tistically significant, this difference can only be attributed to the pretransplant 
transfusions, since a considerable number of recipients (3 (4) of 8) are now long-
term survivors(> I year) and are off immunosuppression, a phenomenon which ne-
ver occurs without previous transfusions. 
The differential expression of the transfusion effect using different immunosup-
pressants must be due to the interaction of these agents with the various components 
of the immune response that are involved in the immune reaction evoked by the ad-
ministration of third-party blood and/or other tissue antigens. Sufficient evidence is 
now available to assume that blood transfusions induce both specific and nonspeci-
fic T suppressor cells (Marque! et al., 1982, Lenhard et al., 1982). In nonimmuno-
suppressed rats, these transfusion induced suppressor cells have been shown to cau-
se prolonged graft survival in an adoptive cell transfer model, dependent upon the 
number of cells transferred (Marque! eta!., 1982). Assuming that these cell media-
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ted suppressor mechanisms are responsible for the prolonged graft survival follo-
wing transfusion, it can be speculated that the combination of Aza/Pred probably 
affects not the suppressor mechanism but rather the cytotoxic component of the im-
mune response. 
CyA obviously acts in a different manner. Although its working mechanism is not 
fully elucidated, CyA appeared to inhibit especially T helper cells in a reversible way 
(Homan et al., 1980e); suppressor cell induction and expression were found to be 
unaffected on the other hand (Leapman et al., 1981; Hess et al., 1981; Morris, 
1981b). It seems that CyA temporarily stops the immunologic clock set to work by 
the introduction of antigens; when CyA was no longer administered, rejection oc-
curred at a control survival time if calculated from that very time. II may be that 
CyA blocks the immune response in vivo in a rather nonselective manner. Prelimi-
nary experiments in the rat model showed that it may affect the prolonged heart 
graft survival seen after adoptive cell transfer from blood conditioned syngeneic rats 
(Marque! and Niessen, unpublished results). In the latter experiment, it was shown 
that rats receiving 100 x 106 mononuclear cells from blood conditioned syngeneic 
rats showed no permanent graft survival if they were treated with CyA at transfer, 
as opposed to animals that were not treated with Cy A. This may suggest that Cy A 
does indeed also inhibit suppressor cells, but it may also be that Cy A blocks the acti-
on of certain immunocompetent cells or perhaps T helper cells that are essential for 
the expression of the transfusion effect. 
A comparable explanation would apply to the absence of the transfusion effect in 
dogs. 
It was demonstrated in the rat model that postoperative admmistration of CyA in 
the BN/Ro to WAG/Ro donor recipient combination did not alter the permanent 
graft survival that is seen following donor specific blood transfusion. This observa-
tion would be in accord with the supposed suppressor cell sparing effect of CyA. 
Still, it cannot be excluded that merely the immunosuppressive effect of CyA is ma-
nifested in this relatively weak donor recipient combination, because CyA could 
also induce permanent graft survival in nonconditioned recipients at similar dosa-
ges. 
Using the reverse donor recipient combination, viz. BN/Ro to W AG/Ro, it was 
found that CyA at a dose of 15 mg/kg/day could effectively overcome the deleteri-
ous effect of sensitization by donor specific blood transfusion, which normally re-
sults in accelerated heart graft rejection. This finding is at variance with other stu-
dies reporting that CyA does not prevent graft rejection in sensitized animals (Mor-
ris, 1981b). The above findings may be promising with respect to the treatment of 
sensitized transplant patients. However, preliminary findings in the same rat model 
indicate that sensitization by donor heart or skin grafts is more difficult to overcome 
with high doses of Cy A. Following sensitization by a donor strain heart, permanent 
survival of a second heart graft can eventually be obtained in 40o/o of recipients 
using CyA at doses of 15-30 mg/kg/day for seven days. Sensitization by donor skin 
grafts, which is normally followed by accelerated rejection of a subsequent heart 
graft, can only be modified to prolonged but not to indefinite graft survival using 
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these high doses of Cy A. 
Transfused recipients who are treated with CyA as the only immunosuppressant 
following transplantation do not benefit from the transfusions administered, unless 
they are converted from Cy A to Aza/Pred. On the other hand, the immunosuppres-
sive potency of CyA alone may prove to be sufficient to maintain graft survival. 
Further clinical studies using Cy A will have to establish its place in the treatment of 
kidney graft recipients. For the time being, most patients are still being treated with 
the conventional immunosuppressants azathioprine and prednisolone and many will 
still have the benefit of prolonged graft survival when the combination of pre-
transplant blood transfusions and postoperative immunosuppression is used. 
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SUMMARY 
Kidney transplantation is presently the therapy of choice for end-stage renal failure. 
The major threat for a graft remains rejection, despite all efforts and recent advan-
ces in the area of transplantation biology. Although graft survival has been impro-
ved only moderately, patient mortality has decreased considerably during the last 
decade. The three mainstays in the treatment of transplant patients are pre-
transplant blood transfusions, chemical nonspecific immunosuppression and histo-
compatibility matching. It was only recently established that pretransplant blood 
transfusions can prolong kidney graft survival. However, several parameters regar-
ding the type and number of transfusions remained to be determined to obtain the 
optimal effect from a deliberate blood transfusion "therapy". It had not previously 
been investigated to what extent immunosuppression influences the expression of 
the transfusion effect. In particular, little was known about the effect of the new im-
munosuppressant cyclosporin A in blood conditioned recipients. As a matter of 
fact, the presence of a transfusion effect had been confirmed only for postoperative 
immunosuppression by azathioprine and prednisolone. 
The effects of blood transfusion and immunosuppression on the survival of canine 
renal allografts and rat cardiac allografts are described in this thesis. 
In Chapter 1, a review is given of the present state of transplantation, mainly with 
regard to the three modes of treatment mentioned above. Ample attention is paid to 
the properties of cyclosporin A. 
The various materials and methods used are described in Chapter 2. 
Chapter 3 deals with the questions that still remained open and awaiting a definite 
answer before considering a deliberate blood transfusion "therapy". Various blood 
transfusion protocols were studied in the canine renal allograft model. 
It was found that blood transfusions per se, i.e., without azathioprine and predniso-
lone for postoperative immunosuppression, do not prolong kidney graft survival. 
Neither one pretransplant third-party blood transfusion nor three third-party 
plasma transfusions were effective when using conventional postoperative immuno-
suppression. It was concluded that such transfusions dit not provide sufficient 
amounts or types of antigens to induce prolongation of graft survival. However, 
these regimens might have been successful if the animal had been given pretransplant 
immunosuppression. Although only few animals were involved (which precludes a 
decisive answer), peroperative transfusions did not seem to prolong graft survival in 
dogs treated postoperatively with azathioprine and prednisolone. In both man an 
the dog, this topic of the peroperative transfusion effect remains controversial. 
Beagle blood transfusions did not induce a beneficial transfusion effect in beagle 
dogs receiving mongrel kidney grafts. The absence of the transfusion effect was in-
dependent of the fact of whether these transfusions were DLA-matched or DLA-
mismatched. This phenomenon can be attributed to the high degree of inbreeding in 
the beagle. It is suggested that known MHC antigenic differences are not very im-
portant for the induction of the transfusion effect. Matched transfusions seem to in-
duce less sensitization than do mismatched transfusions. 
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Chapter 4 describes the effect of cyclosporin A on heart allograft survival in 
blood conditioned recipients using two rat models. After conditioning with one 
donor-specific pretransplant blood transfusion, accelerated rejection was seen in the 
W AG/Ro to BN/Ro donor recipient combination, whereas permanent survival oc-
curred in the reverse combination. Postoperative administration of cyclosporin A 
for one week did not affect permanent graft survival in blood conditioned 
WAG/Ro recipients, whereas sensitization was overcome in transfused BN/Ro reci-
pients; at a dose of 15 mg/kg Cy A, even permanent graft survival was achieved in 
all BN/Ro recipients. The finding that CyA can be used to prevent graft rejection in 
sensitized recipients was in contrast to the prevailing opinion in the literature. 
Experiments studying the effect of cyclosporin A on kidney graft survival in 
transfused and nontransfused dogs are described in Chapter 5. The influence of the 
combined use of cyclosporin A and the combination of azathioprine and predniso-
lone as well as the effect of conversion from cyclosporin A to conventional immuno-
suppression were also studied. A beneficial blood transfusion effect could not be 
observed during the use of cyclosporin A for postoperative immunosuppression, ei-
ther as a single agent or in combination with azathioprine and prednisolone. When 
the administration of cyclosporin A was stopped and the conventional immunosup-
pressants continued, a beneficial transfusion effect was again observable. Obvi-
ously, azathioprine and prednisolone are necessary for the expression of the blood 
transfusion effect. Using cyclosporin A as the only immunosuppressant, a clear do-
se response relationship was seen for kidney graft survival. At a dose of 25 
mg/kg/day all recipients survived the duration of the cyclosporin A administration. 
After conversion from a high (e.g., 25 mg/kg/day) dose of CyA to conventional im-
munosuppressants, a markedly prolonged graft survival which could not be explai-
ned solely by the immunosuppressive effect of azathioprine and prednisolone was 
observed. In the present dog model, altered kidney function seemed to be a reflecti-
on of suboptimal immunosuppression rather than a reflection of the nephrotoxic ef-
fect of cyclosporin A, which has been described in clinical studies. Shortly after 
transplantation, a slight hepatotoxic effect of cyclosporin A was observed. 
In Chapter 6, the data of the foregoing experimental paragraphs are discussed in a 
wider context. The possible importance of blood transfusions administered to the 
kidney donor is mentioned. Further, reference is made to the recent clinical studies 
employing donor-specific transfusions in one-haplotype related individuals. These 
transfusions have a 30 percent risk of sensitization, but in the nonsensitized reci-
pients a very high early graft survival (98"1o at I year) is observed. Considering the 
mechanism of blood transfusions, it is suggested that T suppressor cells may play an 
important role in the transfusion effect; this could be derived from in vitro studies in 
man and adoptive transfer experiments in the BN/Ro to WAG/Ro rat model. 
At present, most transplant recipients are still treated with azathioprine and pred-
nisolone, which allow for the expression of the transfusion effect. However, in the 
near future, with increased experience in the use of cyclosporin A, the benefits and 
immunosuppressive potency of this new drug might prove to outweigh those of the 
transfusion effect seen when conventional immunosuppression is used. 
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SAMENVATTING 
Niertransplantatie is tegenwoordig de voorkeursbehandeling van patienten met een 
terminate nierinsufficientie. Ondanks aile moderne ontwikkelingen vormt afstoting 
de grootste bedreiging voor een getransplanteerde nier. Wereldwijd gezien is denier-
transplantaat overleving slechts in bescheiden mate verbeterd gedurende de laatste 
tien jaren. De mortaliteit na transplantatie daalde daarentegen aanzienlijk. De hui-
dige behandeling van transplantatie patienten rust in hoofdzaak op drie pijlers: 
postoperatieve farmacologische inmunosuppressie, weefseltypering en de toediening 
van bloedtransfusies aan dialyse patienten v66r transplantatie. Het feit, dat bloed-
transfusies de transplantaat overleving in gunstige zin beinvloeden, is pas sinds kart 
algemeen aanvaard. Om deze "transfusie therapie" optimaal te kunnen toepassen 
moeten echter nag een aantal vragen opgelost worden. Het is bijvoorbeeld niet pre-
cies bekend wat de juiste samenstelling van het transfusaat moet zijn en wat het opti-
male aantal transfusies is om het beste resultaat te verkrijgen. Voorts is nag nooit 
onderzocht in hoeverre de toegediende immunosuppressiva van belang zijn voor het 
tot uitdrukking komen van de beschermende werking van preoperatieve bloedtrans-
fusies. Met name is er nauwelijks iets bekend over het effect van preoperatieve 
bloedtransfusies bij patienten die na transplantatie worden behandeld met het nieu-
we immunosuppressivum cyclosporine A. Bijna aile voorgaande studies naar het ef-
fect van bloedtranfusies werden immers verricht bij patienten die postoperatief aza-
thioprine en prednisolon kregen toegediend. 
ln dit proefschrift worden de effecten van bloedtransfusies en immunosuppressie op 
de transplantaat overleving nader bestudeerd. 
ln Hoofdstuk l word! een actueel overzicht gegeven van de factoren die van be-
lang zijn voor de overleving van niertransplantaten; dit zijn vooral de drie bovenge-
noemde parameters. Oak word! ruim aandacht besteed aan de eigenschappen van 
cyclosporine A. 
In Hoofdstuk 2 worden de gebruikte materialen en methoden beschreven. 
De experimenten, die in Hoofdstuk 3 besproken worden, hebben betrekking op 
de optimale toepassing van "bloedtransfusie therapie" bij niertransplantatie kandi-
daten. Daartoe werden verscheidene bloedtransfusie protocollen uitgetest in het 
hondenmodel. 
Het bleek dat preoperatieve bloedtransfusies per se, zonder postoperatieve toedie-
ning van azathioprine en prednisolon, geen verlenging van transplantaatoverleving 
gaven. Een preoperatieve bloedtransfusie had geen beschermend effect, evenmin als 
drie plasma-transfusies. Wellicht werden met deze transfusies niet die hoeveelheden 
of soorten van antigenen toegediend, welke noodzakelijk zijn om een langere overle-
ving te bewerkstelligen. Mogelijkerwijs zouden deze protocollen wel effect gesor-
teerd hebben indien, naast postoperatieve, ook preoperatieve immunosuppressie 
zou zijn toegediend. Ofschoon slechts een kleine groep honden bloedtransfusies 
kreeg toegediend tijdens operatie, leek deze wijze van toediening niet effectief. Het 
effect van peroperatieve transfusies is dus zowel bij de mens als bij de hand niet een-
duidig. lndien beagle ontvangers preoperatief getransfundeerd werden met beagle 
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bloed, bleek er geen sprake te zijn van een beschermend effect van transfusies. Dit 
uitblijven van het transfusie effect na de toediening van beagle bloed was onafhan-
kelijk van de mate van overeenkomst van MHC antigenen tussen bloeddonor en nie-
rontvanger en was waarschijnlijk te wijten aan de hoge mate van inteelt in de beagle. 
Bloedtransfusies met een maximale hoeveelheid overeenkomende weefsel antigenen 
gaven wei in mindere mate aanleiding tot sensibilisatie, zoals viel af te lezen aan het 
aantal positieve kruisproeven. 
In Hoofdstuk 4 wordt de invloed van cyclosporine A op de harttransplantaat 
overleving in ratten bestudeerd. Daarvoor werden twee donor-ontvanger combina-
ties gebruikt, waarin de ontvangers tegengesteld reageerden op donor-specifieke 
bloedtransfusies. In de BN/Ro naar W AG/Ro combinatie geeft een preoperatieve 
donor bloedtransfusie permanente overleving van een heterotoop harttransplantaat, 
terwijl in deW AG/Ro naar BN/Ro combinatie na toediening van donor bloed juist 
versnelde afstoting optreedt. Postoperatieve toediening van cyclosporine A aan ge-
transfundeerde WAG/Ro ontvangers bleek eveneens gepaard te gaan met perma-
nente transplantaat overleving. Ook in de W AG/Ro naar BN/Ro donor-ontvanger 
combinatie werd verlengde of zelfs permanente transplantaat overleving verkregen 
indien getransfundeerde BN/Ro ontvangers behandeld werden met cyclosporine A. 
Bij een dosering van 15 mg/kg/dag werd in alle gevallen permanente transplantaat 
overleving gezien. Kennelijk kan cyclosporine A ook afstoting voorkomen in gesen-
sibiliseerde ontvangers, hetgeen op grand van voorgaande publicaties onwaarschijn-
lijk leek. 
In Hoofdstuk 5 word! het effect van cyclosporine A op de niertransplantaat over-
leving in honden besproken; vooral de expressie van het bloedtransfusie effect bij 
postoperatieve toediening van cyclosporine A en/ of conventionele immunosuppres-
sie staat daarbij centraal. Daarnaast komt ook de invloed van gelijktijdige toedie-
ning van azathioprine en prednisolon, alsook het effect van omschakeling van cy-
closporine A naar deze conventionele immunosuppressiva, ter sprake. 
Preoperatieve bloedtransfusies bleken geen additionele verlenging van de transplan-
taat overleving te bewerkstelligen, indien postoperatief cyclosporine A werd toege-
diend. Ook indien dit middel werd toegepast in combinatie met conventionele im-
munosuppressie werd geen transfusie effect waargenomen. Slechts indien de cy-
closporine A toediening werd gestaakt en de conventionele immunosuppressiva wer-
den gecontinueerd, tract er een verlenging van overleving op in getransfundeerde 
ontvangers in vergelijking met de niet getransfundeerde controle groep. Azathiopri-
ne en prednisolon bleken dus onontbeerlijk voor de expressie van het transfusie ef-
fect. Bij gebruik van cyclosporine A werd een dosis-afhankelijke verlenging van de 
overleving gezien. Als een dosis van 25 mg/kg/dag werd toegediend, overleefden ai-
le ontvangers de tijdsduur van toediening, waaruit blijkt dat de immunosuppressie-
ve werking van cyclosporine A aileen voldoende is om afstoting te voorkomen, mils 
toegediend in een adequate dosering. De gestoorde nierfunctie, die bij doseringen 
van 5 of 10 mg/kg meer uitgesproken was, leek in het onderhavige hondenmodel 
niet te berusten op een nefrotoxisch effect van cyclosporine A, maar op de aanwe-
zigheid van een chronische afstotingsreactie ten gevolge van onvoldoende immuno-
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suppressie. De hepatotoxiciteit van cyclosporine A leek gering en in ieder geval sig-
nificant minder dan bij conventionele immunosuppressie. 
De gegevens van de voorgaande hoofdstukken worden in Hoofdstuk 6 in een rui-
mere context besproken. Ook wordt melding gemaakt van recente ontwikkelingen 
zoals het mogelijkerwijze belangrijke effect van bloedtransfusies die aan de nierdo-
nor worden toegediend en het gebruik van donor-specifieke bloedtransfusies bij ver-
wante niertransplantaties, waarbij nierdonor en -ontvanger een haplotype van el-
kaar verschillen. Donor-specifieke transfusies veroorzaken bij deze laatste groep pa-
tienten in 30"7o van de gevallen sensibilisatie; in niet gesensibiliseerde ontvangers 
daarentegen is de niertransplantaat overleving na I jaar zeer hoog (tot 98%). Op ba-
sis van de bekende gegevens lijkt het aannemelijk dat suppressor T cellen een belan-
grijke rol spelen bij het tot uitdrukking komen van het beschermende effect van 
bloedtransfusies. Vooral in vitro studies met humane cellen en "adoptive transfer" 
experimenten in het BN/Ro naar WAG/Ro rattenmodelleveren daartoe belangrijke 
aanwijzingen. 
Thans wordt de meerderheid van de transplantatie patienten nog steeds behandeld 
met azathioprine en prednisolon, waarbij het beschermend effect van preoperatieve 
bloedtransfusies ondubbelzinnig werd aangetoond. In de nabije toekomst zal blij-
ken in hoeverre de resultaten bij gebruik van cyclosporine A beter zullen zijn dan bij 
gebruik van azathioprine en prednisolon in combinatie met preoperatieve bloed-
transfusies. 
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